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A B S T R A C T
Background
Cannabis has a long history of medicinal use. Cannabis-based medications (cannabinoids) are based on its active element, delta-9-
tetrahydrocannabinol (THC), and have been approved for medical purposes. Cannabinoids may be a useful therapeutic option for
people with chemotherapy-induced nausea and vomiting that respond poorly to commonly used anti-emetic agents (anti-sickness
drugs). However, unpleasant adverse effects may limit their widespread use.
Objectives
To evaluate the effectiveness and tolerability of cannabis-based medications for chemotherapy-induced nausea and vomiting in adults
with cancer.
Search methods
We identified studies by searching the following electronic databases: Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE, EMBASE, PsycINFO and LILACS from inception to January 2015. We also searched reference lists of reviews and
included studies. We did not restrict the search by language of publication.
Selection criteria
We included randomised controlled trials (RCTs) that compared a cannabis-based medication with either placebo or with a conventional
anti-emetic in adults receiving chemotherapy.
Data collection and analysis
At least two review authors independently conducted eligibility and risk of bias assessment, and extracted data. We grouped studies
based on control groups for meta-analyses conducted using random effects. We expressed efficacy and tolerability outcomes as risk ratio
(RR) with 95% confidence intervals (CI).
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Main results
We included 23 RCTs. Most were of cross-over design, on adults undergoing a variety of chemotherapeutic regimens ranging from
moderate to high emetic potential for a variety of cancers. The majority of the studies were at risk of bias due to either lack of allocation
concealment or attrition. Trials were conducted between 1975 and 1991. No trials involved comparison with newer anti-emetic drugs
such as ondansetron.
Comparison with placebo
People had more chance of reporting complete absence of vomiting (3 trials; 168 participants; RR 5.7; 95% CI 2.6 to 12.6; low quality
evidence) and complete absence of nausea and vomiting (3 trials; 288 participants; RR 2.9; 95% CI 1.8 to 4.7; moderate quality
evidence) when they received cannabinoids compared with placebo. The percentage of variability in effect estimates that was due to
heterogeneity rather than chance was not important (I2 = 0% in both analyses).
People had more chance of withdrawing due to an adverse event (2 trials; 276 participants; RR 6.9; 95% CI 1.96 to 24; I2 = 0%; very
low quality evidence) and less chance of withdrawing due to lack of efficacy when they received cannabinoids, compared with placebo
(1 trial; 228 participants; RR 0.05; 95% CI 0.0 to 0.89; low quality evidence). In addition, people had more chance of ’feeling high’
when they received cannabinoids compared with placebo (3 trials; 137 participants; RR 31; 95% CI 6.4 to 152; I2 = 0%).
People reported a preference for cannabinoids rather than placebo (2 trials; 256 participants; RR 4.8; 95% CI 1.7 to 13; low quality
evidence).
Comparison with other anti-emetics
There was no evidence of a difference between cannabinoids and prochlorperazine in the proportion of participants reporting no nausea
(5 trials; 258 participants; RR 1.5; 95% CI 0.67 to 3.2; I2 = 63%; low quality evidence), no vomiting (4 trials; 209 participants; RR
1.11; 95%CI 0.86 to 1.44; I2 = 0%; moderate quality evidence), or complete absence of nausea and vomiting (4 trials; 414 participants;
RR 2.0; 95% CI 0.74 to 5.4; I2 = 60%; low quality evidence). Sensitivity analysis where the two parallel group trials were pooled after
removal of the five cross-over trials showed no difference (RR 1.1; 95% CI 0.70 to 1.7) with no heterogeneity (I2 = 0%).
People had more chance of withdrawing due to an adverse event (5 trials; 664 participants; RR 3.9; 95% CI 1.3 to 12; I2 = 17%; low
quality evidence), due to lack of efficacy (1 trial; 42 participants; RR 3.5; 95% CI 1.4 to 8.9; very low quality evidence) and for any
reason (1 trial; 42 participants; RR 3.5; 95% CI 1.4 to 8.9; low quality evidence) when they received cannabinoids compared with
prochlorperazine.
People had more chance of reporting dizziness (7 trials; 675 participants; RR 2.4; 95% CI 1.8 to 3.1; I2 = 12%), dysphoria (3 trials;
192 participants; RR 7.2; 95% CI 1.3 to 39; I2 = 0%), euphoria (2 trials; 280 participants; RR 18; 95% CI 2.4 to 133; I2 = 0%),
’feeling high’ (4 trials; 389 participants; RR 6.2; 95% CI 3.5 to 11; I2 = 0%) and sedation (8 trials; 947 participants; RR 1.4; 95% CI
1.2 to 1.8; I2 = 31%), with significantly more participants reporting the incidence of these adverse events with cannabinoids compared
with prochlorperazine.
People reported a preference for cannabinoids rather than prochlorperazine (7 trials; 695 participants; RR 3.3; 95% CI 2.2 to 4.8; I2
= 51%; low quality evidence).
In comparisons with metoclopramide, domperidone and chlorpromazine, there was weaker evidence, based on fewer trials and partic-
ipants, for higher incidence of dizziness with cannabinoids.
Two trials with 141 participants compared an anti-emetic drug alone with a cannabinoid added to the anti-emetic drug. There was no
evidence of differences between groups; however, the majority of the analyses were based on one small trial with few events.
Quality of the evidence
The trials were generally at low to moderate risk of bias in terms of how they were designed and do not reflect current chemotherapy
and anti-emetic treatment regimens. Furthermore, the quality of evidence arising frommeta-analyses was graded as low for the majority
of the outcomes analysed, indicating that we are not very confident in our ability to say how well the medications worked. Further
research is likely to have an important impact on the results.
Authors’ conclusions
Cannabis-based medications may be useful for treating refractory chemotherapy-induced nausea and vomiting. However, methodolog-
ical limitations of the trials limit our conclusions and further research reflecting current chemotherapy regimens and newer anti-emetic
drugs is likely to modify these conclusions.
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P L A I N L A N G U A G E S U M M A R Y
Cannabis-based medicine for nausea and vomiting in people treated with chemotherapy for cancer
Background
As many as three-quarters of people who receive chemotherapy experience nausea (feeling sick) and vomiting (being sick), which many
find distressing. While conventional anti-sickness medicines are effective, they do not work for everyone, all of the time. Therapeutic
drugs based on the active ingredient of cannabis, known as THC (delta-9-tetrahydrocannabinol), have been approved for use as anti-
sickness medicines in some countries.
Review question
This review evaluated how well cannabis-based medicines work for treating nausea and vomiting due to chemotherapy treatment in
people with cancer, and what the side effects were.
Main findings
This review of 23 randomised controlled trials (clinical studies where people are randomly put into one of two ormore treatment groups)
found that fewer people who received cannabis-based medicines experienced nausea and vomiting than people who received placebo
(a pretend medicine). The proportion of people who experienced nausea and vomiting who received cannabis-based medicines was
similar to conventional anti-nausea medicines. However, more people experienced side effects such as ’feeling high’, dizziness, sedation
(feeling relaxed or sleepy) and dysphoria (feeling uneasy or dissatisfied) and left the study due to the side effects with cannabis-based
medicines, compared with either placebo or other anti-nausea medicines. In trials where people received cannabis-based medicines and
conventional medicines in turn, overall people preferred the cannabis-based medicines.
Quality of the evidence
The trials were of generally of low to moderate quality and reflected chemotherapy treatments and anti-sickness medicines that were
around in the 1980s and 1990s. Also, the results from combining studies on the whole were of low quality. This means that we are
not very confident in our ability to say how well the anti-sickness medicines worked, and further research reflecting modern treatment
approaches is likely to have an important impact on the results.
Cannabis-based medicines may be useful for treating chemotherapy-induced nausea and vomiting that responds poorly to commonly
used anti-sickness medicines.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Cannabinoids compared with placebo for chemotherapy-induced nausea and vomiting
Patient or population: people with chemotherapy-induced nausea and vomiting
Intervention: cannabinoids
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Cannabinoids
Absence of nausea
(follow-up)
3 per 100 6 per 100
(1 to 63)
RR 2.0 (0.2 to 21) 96
(2)
⊕⊕©©
low3,5
RR > 1 indicates treat-
ment favours cannabi-
noids
Absence of vomiting
(follow-up)
6 per 100 34 per 100
(16 to 76)
RR 5.7 (2.6 to 12.6) 168
(3)
⊕⊕©©
low3,5
RR > 1 indicates treat-
ment favours cannabi-
noids
Absence of nausea and
vomiting
(follow-up)
11 per 100 32 per 100
(20 to 52)
RR 2.9 (1.8 to 4.7) 288
(3)
⊕⊕⊕©
moderate3
RR > 1 indicates treat-
ment favours cannabi-
noids
Participant preference
(follow-up)
Low-risk value2 RR 4.8 (1.7 to 13) 256
(2)
⊕⊕©©
low3,4
RR > 1 indicates treat-
ment favours cannabi-
noids8 per 100 38 per 100
(14 to 104)
High-risk value2
22 per 100 106
(37 to 286)
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Withdrawal any reason
(follow-up)
10 per 1000 3 per 1000
(0.1 to 7)
RR 0.31 (0.01 to 7) 33
(1)
⊕©©©
very low1,3,5
RR<1 indicates treatment
favours cannabinoids
Withdrawal due to ad-
verse event
(follow-up)
80 per 1000 4 per 1000
(0.0 to 72)
RR 6.9 (1.96 to 24) 276
(2)
⊕©©©
very low1,3,5
RR<1 indicates treatment
favours cannabinoids
*The assumed risk for all outcomes is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Sparse data.
2 The low- and high-risk values are the two extreme proportions of people with a preference for one drug over another.
3 Limitations in the design (cross-over study) and high attrition.
4 Unexplained heterogeneity.
5 Imprecision.
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B A C K G R O U N D
Description of the condition
Nausea and vomiting are considered the most stressful adverse
effects of chemotherapy by people with cancer (Barowski 1984;
de Boer-Dennert 1997; Russo 2014). Up to 75% of all people
with cancer experience chemotherapy-related nausea and vomit-
ing (Schwartzberg 2007), which can lead to depression, anxiety
and a feeling of helplessness, lower quality of life and may affect
chemotherapy adherence (Dodds 1985; Janelsins 2013; Wilcox
1982).
Guidelines that inform standard protocols and algorithms en-
sure best practice in managing chemotherapy-induced nausea and
vomiting (Basch 2011; NCCN2014; Roila 2010).However, stan-
dardised care and clinical decision-making occurs within the con-
text of individualised care, where focus on a person’s preference is
key to reducing chemotherapy-related stress in people with can-
cer. People’s preference for cancer treatment is illustrated by sev-
eral studies that report people’s preferences for specific chemother-
apy regimens based on quality of life (reduced treatment toxic-
ity), rather than treatment efficacy (increased predicted survival)
(Beusterien 2014; Dubey 2005; Kuchuk 2013; Sun 2002). There-
fore, it is important to consider use of all approved anti-emet-
ics that treat chemotherapy-induced nausea and vomiting, where
people may have a preference for one or another type of treatment.
During the 1990s, serotonin (5-HT3) receptor antagonists, com-
bined with dexamethasone, became the gold standard in the
prevention of vomiting caused by chemotherapy (Gralla 1999;
MASCC 1998). Episodes of chemotherapy-induced nausea and
vomiting are classified by distinct clinical phases: acute - within
the first 24 hours of treatment; delayed - following the first 24
hours of treatment and anticipatory - a learned response where
refractory nausea and vomiting have been experienced during pre-
vious chemotherapy cycles, which results in nausea and vomiting
prior to a subsequent treatment cycle (Roila 2010). Nowadays,
the anti-emetics indicated for chemotherapy with high emesis-in-
ducing potential are 5-HT3 receptor antagonists, dexamethasone
and aprepitant given during the acute emetic phase (Basch 2011;
Gralla 2013; NCCN 2014; Olver 2004). However, if there is fail-
ure to respond, or there is an increase in vomiting, this cannot
be corrected by increasing the dose or frequency of administra-
tion of the prophylactic anti-emetics (5-HT3 receptor antagonists,
dexamethasone and aprepitant). People who experience refractory
nausea and vomiting (i.e. people who do not respond to first-
line prophylactic anti-emetics) can have additional anti-emetics
added to their existing prophylactic anti-emetic regimen, such as
a dopamine antagonist (metoclopramide, domperidone), a phe-
nothiazine (prochlorperazine or levomepromazine), an antihis-
tamine (cyclizine) or a butyrophenone (haloperidol) anti-emetic
(Gralla 1999; Gralla 2013). Benzodiazepines (lorazepam) can also
be added to the prophylactic anti-emetic regimen for refractory
people, particularly those who are anxious or experience anticipa-
tory nausea and vomiting (Gralla 1999). Dexamethasone is one of
the most effective anti-emetics for delayed nausea and vomiting,
so people experiencing delayed refractory emesis can be prescribed
an extended course of dexamethasone on a reducing dosage (Gralla
1999; Huang 2004; Ioannidis 2000). More recently, there have
been reports of olanzapine being an effective adjunctive treatment
for refractory nausea and vomiting (Gralla 2013). A second-gen-
eration 5HT3 receptor antagonist, palonosetron, is effective in re-
fractory nausea and vomiting to substitute for a first-generation
5HT3 receptor antagonist (Gralla 2013). In addition, if people are
unable to tolerate oral 5HT3 receptor antagonists, other formula-
tions can be considered such as a 24-hour granisetron transdermal
patch, an orally disintegrating ondansetron melt, or ondansetron
oral film (Gralla 2013). Consideration should also be made for
other formulations of adjunctive anti-emetics, such as buccal or
rectal formulations (Gralla 2013).
According to Walsh 2003, cannabinoids, the active agents de-
rived from cannabis (marijuana), may be considered for control-
ling nausea and vomiting as fourth-line agents. They have been
recommended in international anti-emetic guidelines for the pre-
vention of chemotherapy-induced nausea and vomiting (Gralla
1999). Cannabinoids are thought towork through differentmech-
anisms to other agents given for nausea and vomiting (see: How
the intervention might work) and may be effective in people with
cancer who respond poorly to commonly used agents (Machado
Rocha 2008).
Description of the intervention
Cannabis has been used for medicinal purposes throughout his-
tory (Karniol 2001). It was listed on the American pharmacopoeia
until 1944 (Bonnie 1974), when it was removed due to politi-
cal pressure and was banned in the USA (Walsh 2003). Although
cannabis has not been re-listed on the American pharmacopoeia,
in 1986 the Food and Drug Administration (FDA) authorised the
use of its active element, delta-9-tetrahydrocannabinol (delta-9-
THC), for medical purposes (Walsh 2003), to treat the adverse
effects of nausea and vomiting in people with cancer receiving
chemotherapy (Gralla 1999).
Currently, there are two synthetic delta-9-THC (cannabinoid)
agents that have been evaluated in clinical trials that are ap-
proved for the treatment of nausea and vomiting in people
with cancer treated with chemotherapy. These are oral formula-
tions of trans(+)-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahy-
dro-1-hydroxy-6,6-dimethyl-9H-dibenzo(b,d),pyran-
9-one, nabilone, and l(6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-
trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, dronabinol.
How the intervention might work
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Cannabinoids affect the user by interacting with various receptors
in different areas of the brain (Grotenhermen 2002). To date, two
types of cannabinoid receptors have been identified, termed CB1
and CB2. Two substances naturally occurring in the brain that
bind to and activate CB1 receptors are anandamide (Devane 1992)
and 2-arachidonoylglycerol (2-AG) (Mechoulam 1995; Sugiura
1995). The cannabinoid receptors, and other naturally occurring
substances that bind to them, are collectively termed the ’endo-
cannabinoid system’ (Rodríguez de Fonseca 2005). The blockage
of CB1 cannabinoid receptors induces vomiting, suggesting the
existence of cannabinoid receptors within the areas of the brain
related to nausea and vomiting. This also suggests that the delta-
9-THC anti-emetic activity may be due to stimulation of the CB1
receptor (Darmani 2001).
Why it is important to do this review
A systematic review of randomised controlled trials (RCTs) pub-
lished up to the year 2000 concluded that cannabinoids may be
useful for controlling chemotherapy-induced nausea and vomit-
ing, but that harmful adverse effects may limit their widespread
use (Tramer 2001). This meta-analysis pooled placebo-controlled
and active controlled trials together. Furthermore, a more recently
published systematic review came to a similar conclusion regarding
effectiveness, but did not report on the adverse effects (Machado
Rocha 2008). Cannabinoids are currently rarely used in clinical
practice, and the publication of a systematic review of cannabi-
noids in highly emetic chemotherapywill provide an evidence base
for their use in people with refractory nausea and vomiting.
O B J E C T I V E S
To evaluate the effectiveness and tolerability of cannabis-based
medications for chemotherapy-induced nausea and vomiting in
adults with cancer.
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs of cross-over or parallel group design with active or placebo
control groups, or both.
Types of participants
Adults aged 18 years and over presenting with any type of cancer
and receiving chemotherapeutic treatment, independent of gender
and clinical setting. The chemotherapeutic regimens include drugs
with low, moderate or high emetic potential.
We excluded children and young people aged under 18 years, since
prevention and treatment of chemotherapy-induced nausea and
vomiting, including use of cannabinoids, has been reported in this
population in another Cochrane Review (Phillips 2010).
For the purpose of this review, chemotherapeutic treatments were
those containing cytotoxic systemic anti-cancer treatments.
Two review authors (VL and NS) independently classified che-
motherapeutic regimens, containing one or more chemotherapy
agents as low, moderate, moderate to high, or high emetic poten-
tial using both American Society of Clinical Oncology (ASCO)
guidelines (Basch 2011) and MASCC (Multinational Association
of Supportive Care in Cancer)/European Society for Medical On-
cology (ESMO) guidelines (Roila 2010). We resolved differences
in assessment by discussion.
Types of interventions
Experimental arm: licensed pharmacological interventions based
on cannabinoids derived from cannabis: nabilone and dronabinol
used either as monotherapy or adjunct to conventional dopamine
antagonists.
Control arm: placebo or conventional dopamine antagonists.
Types of outcome measures
Primary outcomes
• Complete control of nausea and vomiting (absence of
episodes of nausea and vomiting without use of rescue
medication) in the acute phase (within 24 hours of treatment
with chemotherapy) and in the delayed phase (after 24 hours’
treatment with chemotherapy) of nausea and vomiting.
• Complete control of vomiting (absence of episodes of
vomiting without use of rescue medication) in the acute and
delayed phases of nausea and vomiting.
• Complete control of nausea (absence of episodes of nausea
without use of rescue medication) in the acute and delayed
phases of nausea and vomiting.
Secondary outcomes
• Withdrawal due to adverse effects of anti-emetic.
• Withdrawal due to any anti-emetic-related reason.
• Withdrawal due to lack of anti-emetic efficacy.
• Cross-over studies only: participant preference for one or
other of the interventions (cannabis or control).
• Incidence of particular adverse effects: ’feeling high’,
sedation, euphoria, dizziness, heightened sense of anxiety or
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agitation (dysphoria), depression, hallucinations, paranoia,
hypotension, focal dystonia, extrapyramidal effects and
oculogyric crisis.
Search methods for identification of studies
We sought papers in all languages and carried out translations
wherever necessary.
Electronic searches
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library, 2015, Issue 1), MEDLINE
accessed via Ovid (from 1966 to January week 3 2015), EMBASE
accessed via Ovid (from1980 to January week 3 2015), PsycINFO
accessed via Ovid (from inception to January week 2 2015) and
LILACS (from inception to January 2015). Appendix 1, Appendix
2, Appendix 3, Appendix 4, and Appendix 5 show the search
strategies.
All relevant articles were identified on PubMed and, using the
’related articles’ feature, we carried out a further search for newly
published articles.
Searching other resources
Unpublished and grey literature
We searched metaRegister (www.controlled-trials.com/rct),
Physicians Data Query (www.nci.nih.gov), wwwclinicaltrials.gov,
and www.cancer.gov/clinicaltrials for ongoing trials. We searched
for conference proceedings and abstracts through ZETOC (
zetoc.mimas.ac.uk) and WorldCat Dissertations.
Handsearching
We examined bibliographical references of all the relevant studies
in detail in order to find studies not identified in the electronic
search, and handsearched key textbooks and previous systematic
reviews and reports of conferences (i.e. ESMO and ASCO).
Data collection and analysis
Selection of studies
We downloaded all the titles and abstracts retrieved by electronic
searching to a reference management database; we removed du-
plicates and three review authors (LS, FA, SB) independently ex-
amined the remaining references. We excluded those studies that
clearly did not meet the inclusion criteria and we obtained copies
of the full text of potentially relevant references. Three review au-
thors (LS, FA, SB) independently assessed the eligibility of the
retrieved papers. The review authors were not blinded to the au-
thors’ names, institutions and journals of publication. We resolved
disagreements by discussion and documented the reasons for ex-
clusion in the Characteristics of excluded studies table.
Data extraction and management
For the included studies, two review authors (FA, LS) indepen-
dently abstracted data on characteristics of study participants (in-
clusion criteria, age, gender, type of cancer and stage of disease, co-
morbidities, co-interventions and chemotherapy regimens); dose,
frequency, route of administration and duration of experimental
and control interventions; risk of bias (seeAssessment of risk of bias
in included studies); outcomes (see Types of outcome measures)
and deviations from the protocol onto a data abstraction form
specially designed for the review and checked by a third author
(SB). We resolved disagreements by discussion or by appeal.
For dichotomous outcomes (such as number of people with che-
motherapy-induced nausea and vomiting per treatment group that
did not present with symptoms of nausea and vomiting, described
as absence of episodes of nausea and vomiting, to the end of the
period of study; or withdrawals), we extracted the number of par-
ticipants in each treatment arm who experienced the outcome of
interest and the number of participants assessed in order to esti-
mate a risk ratio (RR).
Wherever possible, all data extracted were those relevant to an
intention-to-treat analysis, in which participants were analysed in
the groups to which they were assigned. For cross-over studies,
we extracted information on the number of cross-over periods,
duration of washout periods and whether a paired design had been
taken into consideration in the analysis.
We notes the time points at which outcomes were collected and
reported.
Unit of analysis
For cross-over studies, we extracted the number of events as the
numerator and the number analysed as the denominator for each
treatment period.
Assessment of risk of bias in included studies
We assessed the risk of bias in included RCTs using the Cochrane’s
’Risk of bias’ tool (Higgins 2011). This included assessment of:
• method used for generating the randomisation sequence
allocation of participants to the treatment arms;
• allocation concealment;
• blinding (of participants, healthcare providers and outcome
assessors);
• reporting of incomplete outcome data (studies were
considered at high risk of bias if more than 80% of people were
assessed for primary outcomes): proportion of losses to follow-up
and association with treatment arms, reasons for drop-out and
association of drop-outs with treatment arms;
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• selective reporting of outcomes;
• any other sources of bias that were pre-defined as carry-over
effects and unbiased data available for analysis for cross-over
trials.
Three review authors independently applied the ’Risk of bias’ tool
and resolved differences by discussion. We summarised results in
both a ’Risk of bias’ graph and a ’Risk of bias’ summary. We
interpreted results of meta-analyses in light of the findings with
respect to risk of bias.
Measures of treatment effect
For dichotomous outcomes, we calculated the RR and its respec-
tive 95% confidence interval (CI). We incorporated cross-over tri-
als in the meta-analyses using reported summary effect estimates.
Where the carry-over effects were evident for a particular study,
then we only used the data for the first period for the meta-anal-
ysis.
Dealing with missing data
We did not impute missing outcome data for any of the outcomes.
If contact details could be obtained, we contacted trial authors and
requested missing data.
Assessment of heterogeneity
We assessed the heterogeneity between the trials by visual inspec-
tion of forest plots, by estimation of the percentage heterogeneity
between trials that could not be ascribed to sampling variation
(Higgins 2003), and by a formal statistical test of the significance
of the heterogeneity (Deeks 2001). We interpreted the I2 value
according to recommendations in the Cochrane Handbook for Sys-
tematic Reviews of Interventions as follows (Higgins 2011):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
Where there was evidence of substantial heterogeneity, we inves-
tigated and reported the possible reasons for this.
Assessment of reporting biases
We examined funnel plots corresponding to meta-analysis of the
primary outcome if there were at least 10 trials included in the
meta-analysis to assess the potential for small-study effects such as
publication bias.
Data synthesis
Where we judged the trials sufficiently similar, we pooled their
results in a meta-analysis. For dichotomous outcomes, we com-
bined the RR for each study. We used random-effects models with
inverse variance weighting for all meta-analyses due to the clinical
and methodological diversity of the studies (see Characteristics of
included studies table).
If trials had multiple treatment groups, we divided the ’shared’
comparison group into the number of treatment groups and
treated comparisons between each treatment group and the split
comparison group as independent comparisons.
Subgroup analysis and investigation of heterogeneity
We conducted the following subgroup analyses for the primary
outcome if sufficient trials were available:
• history of cannabis use, naive users versus prior users of
cannabis;
• history of exposure to chemotherapy, chemotherapy naive
versus prior chemotherapy treatment;
• type of cannabinoid agent, nabilone versus dronabinol.
Sensitivity analysis
We carried out sensitivity analyses for the primary outcome, if
sufficient trials were available, excluding trials at high risk of bias
and trials of a cross-over design. We also analysed the influence of
the following factors on estimates of treatment effect:
• repeating the analysis excluding trials where
chemotherapeutic regimens had low or low-moderate emetic
potential, or the emetic potential was unclassifiable;
• repeating the analysis excluding trials where the primary
outcome data were gathered after more than 24 hours of
chemotherapeutic treatment.
R E S U L T S
Description of studies
Results of the search
The search identified 441 records of which 135 were potentially
eligible. We obtained hard copies of the full article of these articles
for further consideration and excluded 112 (Figure 1). We iden-
tified no unpublished data.
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Figure 1. Identification and selection of randomised controlled trials for review inclusion.
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Included studies
Of the 23 included RCTs, the majority (19) were of cross-over
design with four that were of parallel group design (Frytak 1979;
Gralla 1984; Lane 1991; Pomeroy 1986).
The RCTs included people with a variety of cancers undergo-
ing different chemotherapy regimens ranging from moderate to
high anti-emetic potential, except for one of low emetic potential
(Chang 1979a); five were unclassifiable as reporting of chemo-
therapy regimen was unclear (Kleinman 1983; Lane 1991; Levitt
1982; Sallan1975a;Ungerleider 1982). Four trialswere conducted
on participants who were cannabis naive (Ahmedzai 1983; Frytak
1979; Johansson 1982; Lane 1991), one where 88% of partici-
pants were naive (Chang 1981), and one where 27% of partic-
ipants were naive (Chang 1979a). One study excluded current
users of cannabis (McCabe 1988), and in the other trials previous
exposure to cannabinoids was unclear.
Nine RCTs compared cannabinoids given as monotherapy com-
pared with placebo (Chang 1979a; Chang 1981; Frytak 1979;
Jones 1982; Kluin-Neleman 1979; Levitt 1982; McCabe 1988;
Sallan 1975a; Wada 1982), with another anti-emetic agent
(prochlorperazine) in 11 RCTs (Ahmedzai 1983; Einhorn 1981;
Frytak 1979;Herman1979; Johansson 1982; Lane 1991;McCabe
1988; Niiranen 1985; Orr 1981; Steele 1980; Ungerleider 1982),
metoclopramide in two RCTs (Crawford 1986; Gralla 1984),
domperidone in one RCT (Pomeroy 1986), and chlorpromazine
in one RCT (George 1983). Cannabinoids were also given as co-
therapy with another anti-emetic agent compared with an anti-
emetic agent alone in two RCTs (Kleinman 1983; Lane 1991).
Two different cannabis-based medications were tested: nabilone
in 12 RCTs (Ahmedzai 1983; Crawford 1986; Einhorn 1981;
George 1983; Herman 1979; Johansson 1982; Jones 1982; Levitt
1982; Niiranen 1985; Pomeroy 1986; Steele 1980; Wada 1982),
and dronabinol in 11 RCTs (Chang 1979a; Chang 1981; Frytak
1979; Gralla 1984; Kleinman 1983; Kluin-Neleman 1979; Lane
1991;McCabe 1988; Orr 1981; Sallan 1975a; Ungerleider 1982).
Dosing schedules varied across trials. Nabilone when given as
monotherapy was administered most commonly as a fixed dose of
2 mg twice daily with lower doses administered when given as co-
therapy. Dronabinol was mainly given at doses according to body
surface area and ranged from 10 mg/m2 twice daily to 15 mg/m
2 six times daily. Both were given as an oral formulations. In two
trials, oral dronabinol was replaced with cannabis-based cigarettes
if the participants vomited (Chang 1979a; Chang 1981).
The majority of the nausea or vomiting (or both) outcomes were
reported for those that occurred within a 24-hour period. How-
ever, for some trials, it was unclear when outcomes were assessed
and theymay have been reported for a longer time-period (Herman
1979; Johansson 1982; Jones 1982; Kluin-Neleman 1979; Lane
1991; Levitt 1982). Trials were conducted between 1975 and
1991.
Excluded studies
We excluded 112 studies for reasons described in the
Characteristics of excluded studies table. The main reasons were
due to not being a primary study (i.e. a review, editorial or letter)
(64) or were a non-randomised single-arm study (eight). RCTs
were excluded due to not being an eligible treatment group (six);
comparison (six) or a relevant outcome (one); recruited children
(three); only presenting preliminary (three) or subsidiary results
(one); having no extractable data (eight) or a duplicate of an ex-
isting study (10). Two were unobtainable.
Risk of bias in included studies
The trials were of variable quality ranging from low to moderate
(Figure 2; Figure 3).
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included trials.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
trial.
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Allocation
Six trials adequately reported how the randomisation sequence
was generated (Chang 1979a; Chang 1981; Frytak 1979; George
1983; Gralla 1984; Ungerleider 1982); the remaining 17 trials
were unclear. Concealment of allocation was adequate in five trials
(Einhorn 1981; Frytak 1979; George 1983; Gralla 1984; Herman
1979), and unclear in the remaining 18 trials.
Blinding
The majority of the trials were described as double-blind, which
was implemented by using identical tablets. Eight were reported as
double-blind, but it was unclear how this was achieved (Crawford
1986; Johansson 1982; Jones 1982; Lane 1991; Levitt 1982; Steele
1980; Ungerleider 1982; Wada 1982), and one study made no
attempt at blinding (McCabe 1988).
Incomplete outcome data
Most trials were prone to attrition bias with only 9/23 trials judged
as low risk of bias.
Selective reporting
All of the trials reported on the incidence of nausea or vomiting
(or both); however, not all contributed to the meta-analyses. We
were unable to include data for trials if they only reported results
for nausea and vomiting as mean frequency of episodes, rather
than the proportion of participants with and without nausea or
vomiting (or both). While a reduction in severity of nausea or
a reduction in vomiting episodes (or both) may be considered a
worthwhile outcome for people with chemotherapy-induced nau-
sea and vomiting, in these included trials, nausea severity was not
measured with a validated instrument and episodes of vomiting
were not analysed using standard methods for such (count) data.
Therefore, we have not reported these data.
Other potential sources of bias
A large proportion of the trials were of cross-over design. We
assumed that the washout period was sufficient and there were no
carry-over effects of treatment due to the gap between chemo-
therapy treatment cycles, which would typically be around three
weeks. The main potential source of bias was due to lack of infor-
mation reported on whether a paired analysis was performed or
not, and it was unclear if the groups were balanced at baseline.
Effects of interventions
See: Summary of findings for the main comparison
Cannabinoids compared with placebo for chemotherapy-induced
nausea and vomiting; Summary of findings 2 Cannabinoids
compared with other anti-emetic agent for chemotherapy-induced
nausea and vomiting; Summary of findings 3 Cannabinoid
plus other anti-emetic agent compared with other anti-emetic
monotherapy for chemotherapy-induced nausea and vomiting
Cannabinoids versus placebo
Nine trials with 819 participants compared cannabinoids with
placebo (Chang 1979a; Chang 1981; Frytak 1979; Jones 1982;
Kluin-Neleman 1979; Levitt 1982;Orr 1981; Sallan 1975a;Wada
1982), although not all trials contributed data for each outcome.
Primary outcome - anti-emetic efficacy
Two trials involving 96 participants showed no evidence of a dif-
ference between groups in the proportion of participants report-
ing complete absence of nausea with cannabinoids compared with
placebo (RR 2.0; 95% CI 0.19 to 21; Analysis 1.1).
Three trials involving 168 participants showed that people had
more chance of reporting complete absence of vomiting when they
received cannabinoids compared with when they received placebo
(RR 5.7; 95% CI 2.6 to 13). The percentage of the variability in
effect estimates that was due to heterogeneity rather than chance
was not important (I2 =0%,Tau2 =0.0,Chi2 test for heterogeneity
P value = 0.33; Analysis 1.2).
Three trials involving 288 participants showed that people had
more chance of reporting complete absence of nausea and vomiting
when they received cannabinoids compared with placebo (RR 2.9;
95% CI 1.8 to 4.7). The percentage of the variability in effect
estimates that was due to heterogeneity rather than chance was
not important (I2 = 0%, Tau2 = 0.0, Chi2 test for heterogeneity P
value = 0.50; Analysis 1.3).
Subgroup analyses, comparing results in trials with cannabis-naive
people to trials where participants either had previous experience
with cannabis or where previous use was unclear, showed no evi-
dence of a difference between the two subgroups (P value = 0.4)
with respect to absence of nausea and vomiting.
Secondary outcome - participant preference
Two trials involving 256 participants showed that people hadmore
chance of reporting a preference for cannabinoids compared with
placebo (RR 4.8; 95%CI 1.7 to 13) with substantial heterogeneity
(I2 = 71%, Tau2 = 0.43, Chi2 test for heterogeneity P value = 0.06;
Analysis 1.9).
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Secondary outcomes - tolerability and adverse events
One trial involving 33 participants showed no evidence of a differ-
ence between groups in the proportion of participants withdraw-
ing for any reason (RR 0.31; 95% CI 0.01 to 7.21; Analysis 1.10).
Participants had more chance of withdrawing due to an adverse
event when they received cannabinoids compared with placebo (2
trials; 226 participants; RR 6.9; 95% CI 2.0 to 24; Analysis 1.11),
and less chance of withdrawing due to lack of efficacy (1 trial; 228
participants; RR 0.05; 95% CI 0.0 to 0.89; Analysis 1.12).
Participants had more chance of reporting ’feeling high’ (3 trials;
137 participants; RR 31; 95% CI 6.4 to 152). The percentage of
the variability in effect estimates that is due to heterogeneity rather
than chance was not important (I2 = 0%, Tau2 = 0.0, Chi2 test
for heterogeneity P value = 0.95; Analysis 1.6).
There was no evidence of a difference between groups in the pro-
portion of participants reporting depression (1 trial; 16 partici-
pants; RR 3.8; 95% CI 0.18 to 80; Analysis 1.4), dysphoria (2
trials; 96 participants; RR 9.0; 95% CI 0.50 to 161; Analysis 1.5),
paranoia (1 trial; 64 participants; RR 3.0; 95% CI 0.13 to 71;
Analysis 1.7), or sedation (2 trials; 139 participants; RR 4.5; 95%
CI 0.35 to 58; Analysis 1.8) with substantial heterogeneity (I2 =
72%, Tau2 = 2.65, Chi2 test for heterogeneity P value = 0.06).
The CIs for the estimates shown above are wide reflecting the
uncertainty of these estimates.
Cannabinoids versus prochlorperazine
Nine trials with 1221 participants compared cannabinoids with
prochlorperazine (Ahmedzai 1983; Frytak 1979; Herman 1979;
Johansson 1982; Lane 1991;McCabe 1988;Niiranen 1985; Steele
1980; Ungerleider 1982), although not all trials contributed data
for each outcome.
Primary outcome - anti-emetic efficacy
Five trials involving 258 participants showed no evidence of a dif-
ference between groups in the proportion of participants report-
ing no nausea (RR 1.5; 95% CI 0.67 to 3.2) with substantial het-
erogeneity (I2 = 58%, Tau2 = 0.33, Chi2 test for heterogeneity P
value = 0.05; Analysis 2.1).
Four trials involving 209 participants showed no evidence of a dif-
ference between groups in the proportion of participants reporting
no vomiting (RR 1.1; 95% CI 0.86 to 1.4). The percentage of the
variability in effect estimates that was due to heterogeneity rather
than chance was not important (I2 = 0%, Tau2 = 0.0, Chi2 test
for heterogeneity P value = 0.53; Analysis 2.3).
Four trials involving 414 participants showed no evidence of a
difference between groups in the proportion of participants re-
porting absence of nausea and vomiting (RR 2.0; 95% CI 0.74 to
5.4) with substantial heterogeneity (I2 = 60%, Tau2 = 0.51, Chi
2 test for heterogeneity P value = 0.06; Analysis 2.5). Sensitivity
analysis, where the two parallel group trials were pooled after re-
moval of the five cross-over trials, had an RR of 1.1 (95% CI 0.70
to 1.7) with no heterogeneity(I2 = 0%, Tau2 = 0.0, Chi2 test for
heterogeneity P value = 0.56).
Subgroup analyses - comparing results in trials with cannabis-naive
people to trials where participants either had previous experience
with cannabis or where previous use was unclear, showed no evi-
dence of a difference between the two subgroups with respect to
absence of nausea (P value = 0.11), but a difference between the
subgroups for absence of nausea and vomiting with a smaller effect
in people with no previous cannabis use (P value = 0.007). We
were unable to conduct a subgroup analysis for absence of vomit-
ing as all trials were of people who were cannabis naive (Analysis
2.6).
In addition, there was no evidence of a difference between sub-
groups comprised of different cannabinoid medications for ab-
sence of nausea (P value = 0.54), absence of vomiting (P value =
0.60) or absence of nausea and vomiting (P value = 0.10). The sub-
group analyses did not explain the source of heterogeneity. There
were insufficient data to perform other subgroup analyses listed in
methods of analysis.
Secondary outcome - participant preference
Seven trials involving 695 participants showed participants had
more chance of reporting a preference for cannabinoids compared
with prochlorperazine (RR 3.2; 95% CI 2.2 to 4.7) with substan-
tial heterogeneity (I2 = 53%, Tau2 = 0.13, Chi2 test for hetero-
geneity P value = 0.05; Analysis 2.17).
Secondary outcomes - tolerability and adverse events
Based on one trial with 42 participants, participants had more
chance of withdrawing for any reason (RR 3.5; 95%CI 1.4 to 8.9;
Analysis 2.18), and due to lack of anti-emetic efficacy (RR 3.5;
95%CI1.4 to 8.9; Analysis 2.20)when they received cannabinoids
compared with prochlorperazine.
Five trials with 664 participants showed participants had more
chance of withdrawing due to an adverse event when they received
cannabinoids compared with prochlorperazine (RR 3.9; 95% CI
1.3 to 12) with unimportant heterogeneity(I2 = 17%, Tau2 = 0.31,
Chi2 test for heterogeneity P value = 0.31; Analysis 2.19).
Participants had more chance of reporting the following adverse
events when they received cannabinoids compared with prochlor-
perazine: dizziness (7 trials; 675 participants; RR 2.4; 95% CI 1.8
to 3.1; unimportant heterogeneity: I2 = 12%, Tau2 = 0.02, Chi2
test for heterogeneity P value = 0.34; Analysis 2.8), dysphoria (3
trials; 192 participants; RR 7.2; 95% CI 1.3 to 39; unimportant
heterogeneity: I2 = 0%, Tau2 = 0.0, Chi2 test for heterogeneity P
value = 0.75; Analysis 2.9), euphoria (2 trials; 280 participants;
RR 18; 95% CI 2.4 to 133; unimportant heterogeneity: I2 = 0%,
Tau2 = 0.00, Chi2 test for heterogeneity P value = 0.47; Analysis
2.10), ’feeling high’ (4 trials; 389 participants; RR 6.2; 95% CI
3.5 to 11; unimportant heterogeneity: I2 = 0%, Tau2 = 0.0, Chi2
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test for heterogeneity P value = 0.75; Analysis 2.11), and sedation
(8 trials; 947 participants; RR 1.4; 95% CI 1.2 to 1.8; moderate
heterogeneity: I2 = 31%, Tau2 = 0.02, Chi2 test for heterogeneity
P value = 0.18; Analysis 2.15).
There was no evidence of a difference between groups in the pro-
portion of participants reporting depression (3 trials; 317 partici-
pants; RR 0.81; 95% CI 0.51 to 1.3; unimportant heterogeneity:
I2 = 0%, Tau2 = 0.0, Chi2 test for heterogeneity P value = 0.47;
Analysis 2.16), hallucinations (2 trials; 144 participants; RR 5.4;
95% CI 0.66 to 44; unimportant heterogeneity: I2 = 0%, Tau2
= 0.0, Chi2 test for heterogeneity P value = 0.80; Analysis 2.12),
postural hypotension (3 trials; 305 participants; RR 1.2; 95% CI
0.52 to 2.9; moderate heterogeneity: I2 = 41%, Tau2 = 0.29, Chi2
test for heterogeneity P value = 0.18; Analysis 2.13), or paranoia (1
trial; 42 participants; RR 3.0; 95% CI 0.13 to 70; Analysis 2.14).
Cannabinoid versus metoclopramide
Two trials with 57 participants compared cannabinoid with meto-
clopramide (Crawford 1986; Gralla 1984), although both trials
did not contribute data for each outcome.
Primary outcome - anti-emetic efficacy
Neither trial reported data for the proportion of participants with
absence of nausea or vomiting (or both) (Crawford 1986; Gralla
1984).
Secondary outcome - participant preference
One trial involving 64 participants showed no evidence of a dif-
ference between groups in the proportion of participants report-
ing a preference for cannabinoids (RR 1.2; 95% CI 0.61 to 2.4;
Analysis 2.17).
Secondary outcomes - tolerability and adverse events
Neither trial reported withdrawals.
Participants had more chance of reporting dizziness (1 trial, 30
participants; RR 12; 95% CI 1.8 to 81; Analysis 2.8), and postu-
ral hypotension (1 trial, 30 participants; RR 17; 95% CI 1.1 to
270; Analysis 2.13) when they received cannabinoids compared
with metoclopramide. The CIs for these estimates were very wide
reflecting the uncertainty of these estimates.
There was no evidence of a difference between groups in the pro-
portion of participants reporting ’feeling high’ (1 trial, 30 partic-
ipants; RR 3.0; 95% CI 0.35 to 26; Analysis 2.11), or sedation
(1 trial; 30 participants; RR 0.93; 95% CI 0.73 to 1.2; Analysis
2.15).The CIs for these estimates were very wide reflecting the
uncertainty of these estimates. There were no dystonic reactions
in either treatment group.
Cannabinoids versus domperidone
One trial with 38participants compared cannabinoids versus dom-
peridone (Pomeroy 1986).
Primary outcome - anti-emetic efficacy
The trial did not report data for the proportion of participants
with absence of nausea or vomiting (or both).
Secondary outcome - participant preference
The trial did not report data for participant preference.
Secondary outcomes - tolerability and adverse events
There was no evidence of a difference between groups in the pro-
portion of participants withdrawing due to lack of efficacy (RR
0.14; 95% CI 0.01 to 2.7; Analysis 2.20) or withdrawal due to an
adverse event (RR 0.14; 95% CI 0.01 to 2.7; Analysis 1.11), with
both estimates based on very low event rates.
Participants had more chance of reporting dizziness when they
received cannabinoids comparedwith domperidone (RR2.8; 95%
CI 1.1 to 7.1; Analysis 2.8).
There was no evidence of a difference between groups in the pro-
portion of participants reporting euphoria (RR 5.0; 95% CI 0.26
to 98; Analysis 2.10), postural hypotension (RR 4.0; 95%CI 0.49
to 33; Analysis 2.13) or sedation (RR 1.2; 95% CI 0.66 to 2.3;
Analysis 2.15).
Cannabinoids versus chlorpromazine
One trial with 20 participants compared cannabinoids with chlor-
promazine (George 1983).
Primary outcome - anti-emetic efficacy
The trial did not report data for anti-emetic efficacy.
Secondary outcome - participant preference
There was no evidence of a difference between groups in partic-
ipants’ preferences for treatment with cannabinoids or chlorpro-
mazine (RR 2.0; 95% CI 0.83 to 4.8; Analysis 2.17).
Secondary outcomes - tolerability and adverse events
The trial did not report data for withdrawals.
There was no evidence of a difference between groups in the pro-
portion of participants reporting euphoria (RR 3.0; 95% CI 0.13
to 70; Analysis 2.10), postural hypotension (RR 7.0; 95%CI 0.95
to 52; Analysis 2.13), or sedation (RR 1.7; 95% CI 0.85 to 3.4;
Analysis 2.15), with few events giving rise to wide CIs around the
point estimates.
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Cannabinoid plus other anti-emetic agent versus
other anti-emetic agent monotherapy
Two trials with 105 participants compared cannabinoid plus other
anti-emetic agent with other anti-emetic agent monotherapy (
Kleinman 1983; Lane 1991), although neither trial contributed
data for all outcomes. The majority of the analyses were based on
one small trial with few events (Lane 1991).
Primary outcome - anti-emetic efficacy
There was no evidence of a difference between groups in the pro-
portion of participants reporting no nausea (RR 11; 95% CI 0.61
to 182; Analysis 3.1).
There was no evidence of a difference between groups in the pro-
portion of participants reporting no vomiting (RR 1.5; 95% CI
0.69 to 3.1; Analysis 3.2).
There was no evidence of a difference between groups in the pro-
portion of participants reporting no nausea or vomiting (RR 1.6;
95% CI 0.68 to 3.6; Analysis 3.3).
Secondary outcome - participant preference
The trials did not report data for participant preference.
Secondary outcomes - tolerability and adverse events
There was no evidence of a difference between groups in the pro-
portion of participants withdrawing due to any reason (RR 1.3;
95% CI 0.41 to 4.2; Analysis 3.9).
There was no evidence of a difference between groups in the pro-
portion of participants withdrawing due to an adverse event (RR
7.0; 95% CI 0.88 to 55; Analysis 3.10).
There was no evidence of a difference between groups in the pro-
portion of participants withdrawing due to lack of efficacy (RR
0.12; 95% CI 0.01 to 2.0; Analysis 3.11).
There was no evidence of a difference between groups in the pro-
portion of participants reporting depression (no participants in
either group; Analysis 3.4), dizziness (RR 2.1; 95% CI 0.21 to 21;
Analysis 3.5), dysphoria (RR 7.3; 95% CI 0.40 to 134; Analysis
3.6), paranoia (RR 5.2; 95% CI 0.27 to 103; Analysis 3.7), or
sedation (RR 1.8; 95% CI 0.48 to 6.4; Analysis 3.8).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Cannabinoids compared with other anti-emetic agent for chemotherapy-induced nausea and vomiting
Patient or population: people with chemotherapy-induced nausea and vomiting
Intervention: cannabinoids
Comparison: other anti-emetic agent
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Other anti-emetic
agent
Cannabinoids
Absence of nausea
(follow-up)
37 per 100 56 per 100
(25 to 118)
RR 1.46 (0.67 to 3.
15)
258
(5)
⊕⊕©©
low3,4
RR >
1 indicates treatment
favours cannabinoids
Absence of vomiting
(follow-up)
Low-risk value2 RR 1.1 (0.86 to 1.4) 209
(4)
⊕⊕⊕©
moderate3
RR >
1 indicates treatment
favours cannabinoids10 per 1 000 11 per 1 000
(9 to 14)
High-risk value2
70 per 100 77 per 100
(60 to 98)
Absence of nausea
and vomiting
(follow-up)
Low-risk value2 RR 2.0 (0.74 to 5.4) 414
(4)
⊕⊕©©
low3,4
RR >
1 indicates treatment
favours cannabinoids1 per 100 2 per 100
(1 to 5)
High-risk value2
1
8
C
a
n
n
a
b
in
o
id
s
fo
r
n
a
u
se
a
a
n
d
v
o
m
itin
g
in
a
d
u
lts
w
ith
c
a
n
c
e
r
re
c
e
iv
in
g
c
h
e
m
o
th
e
ra
p
y
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
5
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
42 per 100 84 per 100
(31 to 227)
Participant prefer-
ence
(follow-up)
23 per 100 64 per 100
(44 to 92)
RR 2.8 (1.9 to 4.0) 799
(9)
⊕⊕©©
low3,4
RR >
1 indicates treatment
favours cannabinoids
Withdrawal any rea-
son
(follow-up)
19 per 100 67 per 100
(27 to 171)
RR 3.5 (1.4 to 9.0) 42
(1)
⊕⊕©©
low1,3
RR<1 indicates treat-
ment favours cannabi-
noids
Withdrawal due to
lack of efficacy
(follow-up)
20 per 100 19 per 100
(1 to 420)
RR 0.97 (0.04 to 21) 118
(2)
⊕©©©
very low1,3,4
RR<1 indicates treat-
ment favours cannabi-
noids
Withdrawal due to
adverse event
(follow-up)
3 per 100 10 per 100
(4 to 24)
RR 3.2 (1.3 to 8.0) 740
(6)
⊕⊕©©
low3,5
RR<1 indicates treat-
ment favours cannabi-
noids
*The assumed risk for all outcomes is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Sparse data.
2 The low- and high-risk values are the two extreme proportions of people with a preference for one drug over another.
3 Limitations in the design (cross-over study) and high attrition.
4 Unexplained heterogeneity.
5 Imprecision.
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Cannabinoid plus other anti-emetic agent compared with other anti-emetic monotherapy for chemotherapy-induced nausea and vomiting
Patient or population: people with chemotherapy-induced nausea and vomiting
Intervention: cannabinoid plus other anti-emetic agent
Comparison: anti-emetic monotherapy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Anti-emetic monother-
apy
Cannabinoid plus other
anti-emetic agent
Absence of nausea
(follow-up)
1 per 100 10 per 100
(0 to 183)
RR 10 (0.61 to 183) 37
(1)
⊕©©©
very low1,2,3
RR > 1 indicates treat-
ment favours cannabi-
noids
Absence of vomiting
(follow-up)
29 per 100 44 per 100
(20 to 90)
RR 1.5 (0.69 to 3.1) 89
(2)
⊕⊕©©
low1,2
RR > 1 indicates treat-
ment favours cannabi-
noids
Absence of nausea and
vomiting
(follow-up)
30 per 100 48 per 100
(20 to 108)
RR 1.6 (0.68 to 3.6) 37
(1)
⊕⊕©©
low1,2
RR > 1 indicates treat-
ment favours cannabi-
noids
Withdrawal any reason
(follow-up)
20 per 100 26 per 100
(8 to 84)
RR 1.3 (0.41 to 4.2) 41
(1)
⊕⊕©©
low1,2
RR <1 indicates treat-
ment favours cannabi-
noids
Withdrawal due to ad-
verse event
(follow-up)
1 per 100 7 per 100
(1 to 55)
RR 7.0 (0.88 to 55) 105
(2)
⊕©©©
very low1,2,3
RR <1 indicates treat-
ment favours cannabi-
noids
Withdrawal due to lack
of efficacy
(follow-up)
20 per 100 2 per 100
(0 to 40)
RR 0.12 (0.01 to 2.0) 41
(1)
⊕⊕©©
low1,2
RR <1 indicates treat-
ment favours cannabi-
noids2
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*The assumed risk for all outcomes is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Sparse data.
2 Limitations in the design (cross-over study) and high attrition.
3 Imprecision.
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D I S C U S S I O N
Summary of main results
The included trials showed that cannabinoids were more effective
than placebo and were similar to conventional anti-emetics for
treating chemotherapy-induced nausea and vomiting. However,
despite causing more adverse events than placebo, overall there
was weak evidence that people receiving chemotherapy for can-
cer preferred cannabinoids to placebo with stronger evidence that
people preferred them to other anti-emetics.
Cannabinoids were highly effective. When compared with
placebo, participants who received cannabinoids were five times
as likely to report complete absence of vomiting, and three times
as likely to report complete absence of nausea and vomiting. Al-
though, some participants were six times more likely to withdraw
from the study due to an adverse event with cannabinoids, other
participants were more likely to withdraw due to lack of efficacy
with placebo. Adverse events associated with cannabinoids were
reported, however, the only one with evidence of a difference be-
tween cannabinoids and placebo was ’feeling high’. Overall, there
was weak evidence that participants preferred cannabinoids to
placebo.
When cannabinoids were compared with conventional anti-
emetic drugs, there was no evidence of a difference for nausea,
vomiting, or nausea and vomiting. The majority of the data for
these analyses were from comparisonwith prochlorperazine.How-
ever, participants were three or four times more likely to with-
draw due to an adverse event with cannabinoids than prochlor-
perazine. Dizziness, dysphoria, ’feeling high’ and sedation were
all more likely with cannabinoids. Dizziness in particular was
more likely with cannabinoids compared with metoclopramide
and domperidone. Overall, there was evidence that participants
preferred cannabinoids to conventional anti-emetics; however, the
majority of the trials were of prochlorperazine.
There may be an additional benefit of administering a cannabi-
noid with another anti-emetic agent. These benefits include re-
duced nausea, vomiting, and nausea and vomiting. Adverse events
were similar to those for comparisons with anti-emetics given as
monotherapy, but there were insufficient data to make firm con-
clusions.
Overall completeness and applicability of
evidence
The trials included in this review were on adults with a wide va-
riety of cancers undergoing a wide range of chemotherapy regi-
mens.Many of the trials included participants whowere refractory
to conventional anti-emetic medications. The synthetic cannabis-
based compounds were given orally and were either dronabi-
nol or nabilone. The most informative RCTs were the ones that
compared a cannabis-based medication with a conventional anti-
emetic, rather than placebo. These trials showed that cannabis-
based medications had similar anti-emetic effects compared with
prochlorperazine and metoclopramide.
Nowadays, people receiving moderate to highly emetogenic che-
motherapy regimens will be prescribed combination prophylactic
anti-emetic regimens including a 5-HT3 antagonist and steroid,
and perhaps also include a neurokinin-1 (NK-1) inhibitor for very
highly emetogenic regimens (NCCN 2015). In the event of a per-
son experiencing breakthrough or refractory, acute chemotherapy-
induced nausea and vomiting, an additional agent from a differ-
ent pharmacological class of anti-emetics would be recommended,
such as metoclopramide, prochlorperazine or lorazepam (NCCN
2015). Cannabis-based anti-emetics offer an alternative additional
anti-emetic agent for breakthrough or refractory acute chemother-
apy-induced nausea and vomiting. Since there is a lack of studies
that compare the use of cannabinoids to 5-HT3 antagonists and
NK-1 inhibitors, this review found no evidence to support the
use of cannabinoids in place of current prophylactic combination
anti-emetic regimens.
Quality of the evidence
Overall, the trials were of variable quality (very low to moderate
by Grading of Recommendations Assessment, Development and
Evaluation (GRADE) approach). Strengths included the use of
blinding by using double-dummy preparations by the majority
of the trials. However, it is possible that the trials were at risk
of observer bias, due to the characteristic adverse effect profile of
cannabinoids. The risk of bias from selective reporting of the pri-
mary outcome was low. The majority of the trials were unclear
with respect to methods used to generate randomisation sequence
and whether randomisation was concealed, so may be at risk of
selection bias. A major weakness lies in the fact that a large pro-
portion of the trials were of cross-over design, and we were unable
to adjust the data to take into account the paired data, which will
result in narrower CIs around effect estimates. Another weakness
was high risk of bias from attrition from the trials. This was largely
due to participants being excluded from analyses in the cross-over
trials if they did not complete all cross-over periods. The sum-
mary of findings are shown in Summary of findings for the main
comparison; Summary of findings 2; and Summary of findings 3.
The quality of the evidence for most outcomes was generally of
low quality. The main reasons were due to risk of bias, imprecise
results due to few studies or few events (or both) and unexplained
heterogeneity. The impact of the downgrading decisions means
that further research is likely to influence the confidence in our
estimates of effects and may change the estimates.
Potential biases in the review process
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Some trials only reported episodes of nausea and vomiting, rather
than the proportion of participants with no nausea and vomiting,
therefore we did not include these results in meta-analyses. We
also analysed dichotomous outcomes from the cross-over studies
without adjusting the analyses, which potentially gives rise tomore
precise (narrower CIs) estimates of effect.
In order to avoid publication bias, we searched for ongoing trials in
clinical trial registry databases; however, we identified no further
trials.
Agreements and disagreements with other
studies or reviews
Our findings are in broad agreement with previously published
systematic reviews (Machado Rocha 2008; Tramer 2001).We have
updated and extended these earlier reviews by pooling placebo-
controlled trials separately from trials with active comparison
groups, and where cannabis was given as co-therapy with another
anti-emetic, and reporting on tolerability as well as efficacy out-
comes.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The widespread use of cannabis-based medicines for management
of nausea and vomiting with chemotherapy is unlikely due to the
adverse effects they cause. However, cannabinoids are a useful ad-
junctive treatment to consider for people on moderately or highly
emetic chemotherapy that are refractory to other anti-emetic treat-
ments, when all other options of therapy have been tried. Con-
sideration needs to be made of the adverse effect profile of the
cannabinoids, and how the adverse effects may be exacerbated
with other concurrent anti-emetic treatments, as well as the age
of the person. This systematic review will be valuable evidence for
clinicians and future development of international guidelines to
summarise the evidence available.
Implications for research
Adequate study design is important for anti-emetic studies, ide-
ally using a double-blind trial design that is stratified for known
prognostic factors, such as gender, age, alcohol intake, previous
experience of chemotherapy, emetic potential of chemotherapy
and a person’s susceptibility to motion sickness (DeMulder 1992;
Olver 1992a; Olver 1992b; Pater 1984). It is preferable for people
to be chemotherapy naive and receiving the same chemotherapy
regimens, or, if that is not possible, to receive those of the same
emetogenicity as classified by international guidelines. Uniform
anti-emetic regimens should be used, when comparing an adjunc-
tive anti-emetic being added to the regimen in one arm (Rhodes
1984). Studies that compare the use of newer anti-emetics that
have efficacy for treating refractory nausea and vomiting (olanzap-
ine and palonosetron) with cannabinoids would also be informa-
tive. It is difficult to compare anti-emetic studies (Martin 1992),
due to the variation in anti-emetic doses, routes of administration,
time periods of assessment of nausea and vomiting, assessment of
episodes of nausea and vomiting, and any additional anti-emetics
that may have been administered. It also needs to be clear whether
acute or delayed (or both) nausea and vomiting is being assessed,
and there is also a variation in the definitions of complete response
across studies, which impacts on comparing studies (Pater 1984).
In the original anti-emetic trials, assessment of nausea and vom-
iting has been inconsistent where no reliable and valid measures
have been used, which also impacts on their analysis and interpre-
tation (Pater 1984; Rhodes 1984).
While cross-over trials are attractive to evaluate this type of ther-
apy, they are susceptible to loss of participants if not all cross-
over to the second and subsequent phases of the trial. Following
recommendations of the CONSORT (Consolidated Standards of
Reporting Trials) statement for cross-over studies would improve
interpretation of such studies.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ahmedzai 1983
Methods Randomised, double-blinded, 2-period cross-over study
Participants 34 people (19 (56%) men/15 (44%) women), median age 58 years. All cannabis naive
Tumour types: small cell bronchial carcinoma
Chemotherapy regimen: 2 x 21-day cycles. Cyclophosphamide 1 g/m2, doxorubicin 40
mg/m2 and etoposide (VP-16) 100 mg/m2 day 1; etoposide 100 mg/m2 days 2 and 3;
vincristine 2 mg with methotrexate 50 mg/m2 day 10 followed by folinic acid rescue.
Cyclophosphamide and doxorubicin given IV bolus; VP-16 IV over 1-2 hours
Chemotherapy emetogenicity: High
Interventions Nabilone 2 mg orally twice daily x 3 days, n = 34
Prochlorperazine 10 mg orally 3 times daily x 3 days, n = 34
Outcomes Episodes and frequency of nausea and vomiting day 1; withdrawal due to adverse effects;
withdrawals due to death; participant preference due to adverse effects; incidence of
feeling high, euphoria, postural dizziness, dysphoria
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 8/34 (24%) participants withdrew
Selective reporting (reporting bias) Low risk Data reported for primary outcome
Other bias Unclear risk Approximately 10 days’ washout period.
Unclear if paired analysis was performed.
Unclear if groups were balanced at baseline
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double dummy tablet”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding assumed as study reported as
“double-blind” and dummy tablet used
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Chang 1979a
Methods Randomised, double-blind, 3-period cross-over, placebo-controlled trial
Participants 15 people (10/15 (67%) men/5/15 (33%) women) aged 15-49 years (median = 24 years)
. 4/15 (27%) participants were cannabis naive
Tumour type: osteogenic sarcoma
Chemotherapy regimens: methotrexate 250 mg/kg with leucovorin calcium rescue every
3 weeks for 18 months
Chemotherapy emetogenicity: low
Interventions Dronabinol 10 mg/m2 orally every 3 hours for total 5 doses (Phase I), n = 15.
If participant vomited during this period oral dose was replaced with THC cigarette for
remaining doses
Placebo, n = 15
Outcomes Episodes of nausea and vomiting on day of therapy; frequency and severity of nausea;
episodes of sedation, euphoria, dizziness, depression, paranoia
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Order of THC-placebo administration
was randomized into three paired trials”
Allocation concealment (selection bias) Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 58/77 (75%) participants received THC,
39/53 (74%) participants received placebo
Selective reporting (reporting bias) Low risk Data reported for primary outcome
Other bias Low risk Groups balanced at baseline
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Identical gelatin capsules with sesame oil”.
“Identical cigarettes, the odour and taste
of a lit placebo cigarette were identical to
those of cannabis cigarette”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding assumed as study reported as
“double-blind”
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Chang 1981
Methods Randomised, double-blind, 3-period cross-over trial
Participants 8 people (6/8 (75%) men/2/8 (25%) women) aged 17-58 years (median = 41 years),
7/8 (88%) participants were cannabis naive
Tumour types: resected soft tissue sarcoma
Chemotherapy regimen: adjuvant doxorubicin and cyclophosphamide every 4 weeks
until a total cumulative doxorubicin dose of 500-550 mg/m2 Doxorubicin (70 mg/m2)
and cyclophosphamide (700 mg/m2) were given at constant doses for all participants
Chemotherapy emetogenicity: high
Interventions Dronabinol 10 mg/m2 orally every 3 hours for total 5 doses, if vomited then participant
given marijuana cigarettes 900 mg, containing THC 1.93% (approximately 17.4 mg),
n = 8
Placebo, n = 8
Outcomes Episodes of nausea and vomiting on day of therapy
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Order of THC-placebo administration
was randomized into paired trials”
Allocation concealment (selection bias) Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 17/27 (63%) participants received THC,
16/27 (59%) participants received placebo
Selective reporting (reporting bias) Low risk Data reported for primary outcome
Other bias Unclear risk Assumed washout period sufficient. Paired
analysis was performed. Unclear if groups
balanced at baseline
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Identical gelatin capsules with sesame oil.
Identical cigarettes, the odour and taste of a
lit placebo cigarette were identical to those
of cannabis cigarette”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding assumed as study reported as
“double-blind”. “Neither patients nor
nursing staff was [sic] informed which drug
was administered”
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Crawford 1986
Methods Randomised, 2-period cross-over study
Participants 32 people
Tumour type: adenocarcinoma of the ovary or germ cell tumours
Chemotherapy regimen: cisplatin 100 mg/m2, cyclophosphamide and doxorubicin (for
people with adenocarcinoma of ovary), cisplatin 120 mg/m2, methotrexate and vin-
cristine (for people with germ cell tumours). No information on doses reported
Chemotherapy emetogenicity: high
Interventions Nabilone 1 mg orally every 8 hours, n = 32
Metoclopramide 1 mg/kg IV every 3 hours, n = 32
Outcomes Episodes of vomiting during 24 hours, nausea, dizziness, euphoria and drowsiness
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 7/32 (22%) participants received the 4
planned treatment and only 37/64 (58%) par-
ticipants received 1 or 2 treatment episodes
of nabilone and 39/64 (61%) participants re-
ceived 1 or 2 treatment episodes of metochlo-
pramide
Selective reporting (reporting bias) Low risk Data reported for primary outcome
Other bias High risk Assumed washout period sufficient. Paired
analysis was not performed. Unclear if groups
were balanced at baseline
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported as “double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding assumed as study reported as “dou-
ble-blind”
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Einhorn 1981
Methods Randomised, prospective, double-blind, 2-period cross-over study
Participants 100 people aged 15-74 years, mean = 28 years
Tumour type; sarcoma (1 person), Hodgkin’s disease (2 people), lymphoma (4 people),
bladder carcinoma (3 people), testicular carcinoma (70 people)
Chemotherapy regimens: doxorubicin hydrochloride and cyclophosphamide (1 per-
son), nitrogen mustard, vincristine, prednisone and procarbazine (2 people), cyclo-
phosphamide, doxorubicin hydrochloride, vincristine and prednisone (4 people), cis-
platin, doxorubicin hydrochloride and 5-fluorouracil (3 people), cisplatin, vinblastine
andbleomycin (45people), cisplatin, vinblastine, bleomycin anddoxorubicin hydrochlo-
ride (25 people). No information on doses reported
Chemotherapy emetogenicity: high
Interventions Nabilone 2 mg, orally every 6 hours, n = 100
Prochlorperazine 10 mg, orally every 6 hours, n = 100
Outcomes Episodes of nausea and vomiting during 24 hours of therapy; frequency of vomiting;
withdrawal due to adverse effects; withdrawal due to early death and change of chemo-
therapy; episodes of ’feeling high’, depression, hallucination, paranoia, hypotension
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk “Identical capsules used”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 80/100 (80%) par-
ticipants received nabilone, 80/100 (80%)
participants received prochlorperazine
Selective reporting (reporting bias) Low risk Data reported for primary outcome
Other bias Unclear risk Assumed washout period sufficient. Un-
clear if paired analysis was performed. Un-
clear if groups were balanced at baseline
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported as “double-blind”, identical cap-
sules used
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding assumed as study reported as
“double-blind”, identical capsules used
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Frytak 1979
Methods Randomised, double-blind, parallel group trial
Participants 116 people, median age = 61 years. All cannabis naive. THC n = 38 (22 men/16 women)
, prochlorperazine n = 41 (21 men/20 women), placebo n = 37 (27 men/10 women)
Tumour types: colorectal cancer (28 people), gastric cancer (7 people), liver cancer (2
people), miscellaneous (1 person), gastric surgery (5 people), hepatic metastasis (20
people)
Chemotherapy regimens: 5-fluorouracil and semustine or 5-fluorouracil and semustine
plus triazinate, razoxane, doxorubicin or vincristine. 5-fluorouracil 300-350 mg/m2 IV
for 5 days. Semustine 110-175 mg/m2 day 1 only
Chemotherapy emetogenicity: moderate
Interventions Dronabinol 15 mg on day 1, 2 hours prior to chemotherapy, then 2 and 8 hours after
initiation of chemotherapy. Then 3 times daily x 3 days orally, n = 38
Prochlorperazine 10 mg on day 1, 2 hours prior to chemotherapy, then 2 and 8 hours
after initiation of chemotherapy. Then 3 times daily x 3 days orally, n = 41
Placebo n = 37
Outcomes Episodes of nausea and vomiting during 24 hours, sedation, feeling high; withdrawal
due to intolerable central nervous system toxicity or excessive vomiting
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers
Allocation concealment (selection bias) Low risk Drugs dispensed in individual packets
identified by code number
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 1/117 (0.8%) participants withdrew.
After day 1, 10/38 (26%) participants
withdrew in THC group, 5/41 (12%)
participants withdrew in prochlorperazine
group, 3/37 (8%) participants withdrew in
placebo group
Selective reporting (reporting bias) Low risk Data reported for primary outcome
Other bias Low risk Groups were balanced at baseline
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Identical opaque gelatin capsules”
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Frytak 1979 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding assumed as study reported as
“double-blind”
George 1983
Methods Randomized double-blind 2-period cross-over study
Participants 20 people, mean age 54.1 years
Tumour type: advanced gynaecological cancer who vomited during the first chemother-
apy treatment
Chemotherapy regimen: cis-platinum (50 mg/m2) with hydration. Vomited during the
first treatment. Doxorubicin (40 mg/m2), cyclophosphamide (600 mg/m2) and cis-
platinum (11 people); cyclophosphamide 600 mg and cis-platinum (3 people); cis-
platinum (6 people)
Chemotherapy emetogenicity: high
Interventions Nabilone 1 mg 24 hours before chemotherapy then 1 mg 3 times daily orally
Chlorpromazine 12.5 mg IM before chemotherapy with additional dose if requested
Outcomes Number of vomiting episodes in 24 hours, participant preference, adverse events
Notes Translated from French
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly allocated by lottery
Allocation concealment (selection bias) Low risk Identical placebo
Incomplete outcome data (attrition bias)
All outcomes
Low risk All people were included in the analysis
Selective reporting (reporting bias) Low risk Data reported for primary outcome
Other bias Low risk There was no evident difference caused by
the order of administration of the drugs
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical placebo, double-dummy tablets
used
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding assumed as study reported as dou-
ble-blind
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Gralla 1984
Methods Randomised, double-blinded parallel group trial
Participants 31 people (23 men/ 5 women). THC n = 15 (13 men/2 women), aged 39-72 years
(median = 58 years); metoclopramide n = 16 (11 men/5 women), aged 45-70 years
(median = 58 years)
Tumour types: bronchogenic carcinoma (12 people), oesophageal carcinoma (2 people)
, head and neck carcinoma head and neck carcinoma (1 person)
Chemotherapy regimens: all receiving first course of cisplatin 120 mg/m2 IV
Chemotherapy emetogenicity: high
Interventions Dronabinol 10 mg/m2 1.5 hours prior to chemotherapy, then at 1.5, 4.5, 7.5 and 10.5
hours after chemotherapy orally, n = 15
Metoclopramide, 2 mg/kg 30 minutes prior to chemotherapy, then 1.5, 3.5, 5.5 and 8.
5 hours after chemotherapy IV, n = 16
Outcomes Episodes of nausea and vomiting during 24 hours, sedation, dizziness, orthostatic hy-
potension, feeling high
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Paired design inwhich one patient in every
pair was randomly assigned to each treat-
ment”
Allocation concealment (selection bias) Low risk “Identical vials and capsules used”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 15/15 (100%) participants received THC,
15/16 (94%) participants received meto-
clopramide
Selective reporting (reporting bias) Low risk Data reported for primary outcome
Other bias Unclear risk Unclear if groups were balanced at baseline
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Identical vials and capsules used”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding assumed as study reported as
“double-blind”
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Herman 1979
Methods Randomised, double-blinded, 2-period cross-over study
Participants 152 people (126 men/26 women) aged 15-74 years (median = 33 years)
Tumour type: testicular carcinoma (70 people), non-Hodgkin’s disease (12 people),
Hodgkin’s disease (11 people)
Chemotherapy regimen: cisplatin daily for 5 days, vinblastine and bleomycin (70 people)
; cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP 12 people); nitro-
gen mustard (mechlorethamine?), vincristine, procarbazine and prednisone (MOPP 11
people); other regimens included dactinomycin, dacarbazine, 5-fluorouracil, melphalan
and nitrosourea compounds. No information on doses reported
Chemotherapy emetogenicity: high
Interventions Nabilone 2 mg, every 8 hours orally, n = 152
Prochlorperazine 10 mg, every 8 hours orally, n = 152
Outcomes Episodes of nausea and vomiting daily during chemotherapy; withdrawal due to adverse
effects; episodes of somnolence, dizziness, depression, euphoria, preference
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk “Drugs packaged in identical containers
marked only with a number code”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 113/152 (74%) participants
received nabilone, 113/152 (74%) partici-
pants received prochlorperazine
Selective reporting (reporting bias) Low risk Data reported for primary outcome
Other bias Unclear risk Assumed washout period sufficient. Un-
clear if paired analysis was performed. Un-
clear if groups were balanced at baseline
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Identical containers marked only with a
number code”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding assumed as study reported as
“double-blind” and “identical containers
marked only with a number code”
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Johansson 1982
Methods Randomised, double-blind, 2-period cross-over study
Participants 27 people aged 18-70 years
Tumour types: cervical cancer (2 people), cancer of fallopian tubes (2 people), ovar-
ian cancer (13 people), testicular cancer (2 people), head and neck cancer (1 person)
, bronchus cancer (1 person), histiocytoma (1 person), fibrosarcoma (1 person), oligo-
dendroma (1 person), lymphoma (2 people)
Chemotherapy regimens: doxorubicin 40 mg/m2, cyclophosphamide 500 mg/m2 and
cisplatinum 50 mg/m2 (11 people) in combination with vinblastine, vincristine or ftora-
fur (tegfur-uracil). Cyclophosphamide 750-1000 mg/m2 and cisplatinum 75 mg/m2
when given as sole agents
Chemotherapy emetogenicity: high
Interventions Nabilone 2 mg twice daily x 4 days orally, n = 27
Prochlorperazine 10 mg twice daily x 4 days orally, n = 27
Outcomes Episodes of nausea and vomiting assessed daily and reported for follow-up at end of anti-
emetic therapy; withdrawal due to lack of efficacy; withdrawal due to hypotension, ver-
tigo and headache; participant preference; episodes of drowsiness, dizziness, depression,
hypotension
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 18/27 (67%) participants re-
ceived nabilone, 18/27 (67%) participants
received prochlorperazine
Selective reporting (reporting bias) Low risk Data reported for primary outcome
Other bias Unclear risk Assumed washout period sufficient. Un-
clear if paired analysis was performed. Un-
clear if groups were balanced at baseline
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported as “double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding assumed as study reported as
“double-blind”
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Jones 1982
Methods Prospective, randomised, double-blind, 2-period cross-over trial
Participants 54 people; aged 20-37 years (n = 9), 38-57 years (n = 23), > 58 years (n = 22)
Tumour types: breast cancer (15 people), lymphoma (12 people), ovarian cancer (8
people), lung cancer (7 people), melanoma (3 people), testicular cancer (2 people),
miscellaneous (7 people)
Chemotherapy regimens: adriamycin-based regimens (25 people), cisplatinum-based
regimens (14people), other combinations (12 people).No information on doses reported
Chemotherapy emetogenicity: high
Interventions Nabilone 2 mg every 12 hours orally, n = 54
Placebo, n = 54
Outcomes Episodes of nausea and vomiting unclear time period of results unclear; withdrawal due to
severe nausea and vomiting; episodes of drowsiness, euphoria, hallucination, hypotension
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 24/54
(44%) participants received nabilone, 24/
54 (44%) participants received placebo
Selective reporting (reporting bias) Low risk Data reported for primary outcome
Other bias Unclear risk Assumed washout period sufficient. Un-
clear if paired analysis was performed. Un-
clear if groups were balanced at baseline
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported as “double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding assumed as study reported as
“double-blind”
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Kleinman 1983
Methods Randomised, double-blind, 4-period cross-over study
Participants 16 people (9 men/7 women) aged 18-53 years (median = 38 years)
Tumour types: not reported
Chemotherapy regimens: “Cancer chemotherapy known to cause acute gastrointestinal
toxicity”
Chemotherapy emetogenicity: unable to classify
Interventions Prochlorperazine 10 mg + dronabinol 15 mg x 2 courses orally, n = 16
Prochlorperazine + placebo orally, n = 16
Outcomes Episodes of nausea and vomiting 24 hours after chemotherapy, euphoria, sedation
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk 28/32 (87.
5%) participants received prochlorperazine
+ THC, 24/32 (75%) participants received
prochlorperazine + placebo (overall 52/64
(81%) participants received either of the 2
courses)
Selective reporting (reporting bias) Low risk Data reported for primary outcome
Other bias Unclear risk Assumed washout period sufficient. Un-
clear if paired analysis was performed. Un-
clear if groups were balanced at baseline
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported as “double-blind” and “identical
capsules used”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding assumed as study reported as
“double-blind and identical capsules used”
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Kluin-Neleman 1979
Methods Randomised, double-blind, 2-period cross-over study
Participants 11 people (10 men/1 woman) aged 21-53 years
Tumour types: Hodgkin’s or non-Hodgkin’s lymphoma
Chemotherapy regimens: mitoxine 6 mg/m2 (maximum 10 mg), vincristine 1.4 mg/m
2 (maximum 2 mg) IV on days 1 and 8. Procarbazine 100 mg/m2 and prednisone 40
mg/m2 oral days 1-14 for 6 cycles with intervals of 2 weeks
Chemotherapy emetogenicity: high
Interventions Dronabinol 10 mg/m2 orally, n = 11
Placebo, n = 11
Outcomes Episodes of nausea and vomiting at end of day of therapy, feeling high, dizziness, hallu-
cinations
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 17 participants received THC, 11 partici-
pants received placebo
Selective reporting (reporting bias) Low risk Data reported for primary outcome
Other bias Unclear risk Washout period 2 weeks. Unclear if paired
analysis was performed. Unclear if groups
were balanced at baseline
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Identical gelatin capsules were used”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding assumed as study reported as
“double-blind” and “identical gelatin cap-
sules used”
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Lane 1991
Methods Randomised, double-blind, parallel group study
Participants Dronabinol n = 21 (10 men/11 women) aged 20-68 years (median = 47 years), prochlor-
perazine n = 21 (10 men/11 women) aged 22-64 years (median = 49 years), dronabinol
plus prochlorperazine n = 20 (9 men/11 women) aged 25-65 years (median = 55.5 years)
. Total n = 62 (29 men/33 women) aged 20-68 years (median = 52 years)
All cannabis naive
Tumour types: breast cancer (24 people), colon cancer (3 people), lung cancer (8 people)
, lymphoma (17 people), miscellaneous (10 people)
Chemotherapy regimens: cyclophosphamide and doxorubicin (26 people), 5-fluo-
rouracil (14 people), vincristine (13 people), etoposide (10 people), No information on
doses reported. 48/62 participants received chemotherapy with high emetogenic poten-
tial
Chemotherapy emetogenicity: unable to classify
Interventions Dronabinol 10 mg every 6 hours orally, n = 21
Prochlorperazine 10 mg every 6 hours orally, n = 21
Dronabinol 10 mg + prochlorperazine 10 mg orally, n = 20
Outcomes Episodes of nausea and vomiting during chemotherapy treatment; withdrawal due to
adverse effects; episodes of somnolence, dizziness, paranoid reaction, depression
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk 17/21 (81%) participants received dron-
abinol, 20/21 (95%) participants received
prochlorperazine, 17/20 (85%) partici-
pants received dronabinol + prochlorper-
azine
Selective reporting (reporting bias) Low risk Data reported for primary outcome
Other bias Low risk Groups were balanced at baseline
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported as “double-blind”
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Lane 1991 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding assumed as study reported as
“double-blind”
Levitt 1982
Methods Randomised, double-blind, 2-period cross-over study
Participants 58 people aged 17-78 years
Tumour types: lung cancer (21 people), ovarian cancer (11 people), breast cancer (10
people), other cancers (16 people)
Chemotherapy regimens: combinations of doxorubicin, bleomycin, cisplatinum, cy-
clophosphamide, dactinomycin, melphalan, mitomycin C, methotrexate, vincristine,
etoposide, 5-fluorouracil. No information on doses reported
Chemotherapy emetogenicity: unable to classify
Interventions Nabilone, n = 58
Placebo, n = 58
Outcomes Episodes of nausea and vomiting time of assessment unclear, frequency and severity of
nausea, withdrawal due to lack of efficacy, adverse effects, episodes of drowsiness
Notes Dose and duration not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 36/58
(62%) participants received nabilone, 36/
58 (62%) participants received placebo
Selective reporting (reporting bias) Low risk Data reported for primary outcome
Other bias Unclear risk Assumed washout period sufficient. Un-
clear if paired analysis was performed. Un-
clear if groups were balanced at baseline
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported as “double-blind”
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Levitt 1982 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding assumed as study reported as
“double-blind”
McCabe 1988
Methods Randomised, 2-period cross-over trial
Participants 36 (9 men/27 women) aged 18-69 years (median = 48 years)
Tumour types: breast cancer (11 people), haematological malignancies (9 people), sarco-
mas (6 people), gastrointestinal malignancies (5 people), melanoma (2 people), ovarian
cancer (2 people), testicular cancer (1 person)
Chemotherapy regimens: doxorubicin (13 people), cyclophosphamide, methotrexate
and 5-fluorouracil (7 people), nitrogen mustard, vincristine, procarbazine and pred-
nisone (7 people), platinum combinations (4 people), DTIC (2 people), 5-fluorouracil
combinations (2 people), 5-azacytadine (1 person). No information on doses reported
Chemotherapy emetogenicity: moderate to high
Interventions Dronabinol 15 mg/m2 1 hour prior to chemotherapy, then every 4 hours for 24 hours
after chemotherapy orally, n = 36
Prochlorperazine 10 mg 1 hour prior to chemotherapy, then every 4 hours for 24 hours
after chemotherapy orally, n = 36
Outcomes Episodes of nausea and vomiting during 24 hours, feeling high, dizziness, dysphoria,
hallucination, paranoia
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk All people were analysed
Selective reporting (reporting bias) Low risk Data reported for primary outcome
Other bias Unclear risk Assumed washout period sufficient. Unclear
if paired analysis was performed. Unclear if
groups were balanced at baseline
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McCabe 1988 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Blinding not achieved”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Study not blinded
Niiranen 1985
Methods Randomised, double-blind, 2-period cross-over study
Participants 32 people (20 men/4 women) aged 48-78 years, mean = 61 years
Tumour type: lung cancer
Chemotherapy regimen: cyclophosphamide 1.2 g/m2 day 1, etoposide 150 mg/m2 IV
day 1, 250 mg/m2 orally day 3, and vincristine 1.3 mg/m2 days 1 and 8 (5 people);
cyclophosphamide 400 mg/m2, adriamycin 40 mg/m2, cisplatinum 40 mg/m2 every 28
days (8 people); cisplatinum 90 mg/m2 day 1 and vindesine 3 mg/m2 5 x weekly then
twice monthly every 28 days (2 people); cisplatinum 90 mg/m2 day 1 and etoposide 50
mg/m2 days 1-5 every 28 days (9 people); cisplatinum 60 mg/m2 day 1 and etoposide
150 mg/m2 IV day 1 and 200 mg/m2 orally day 3 every 28 days (1 person)
Chemotherapy emetogenicity: high
Interventions Nabilone 1mg orally night before chemotherapy, 1 hour before chemotherapy and every
12 hours up to 24 hours as required orally, n = 32
Prochlorperazine 7.5 mg orally night before chemotherapy, 1 hour before chemotherapy
and every 12 hours up to 24 hours as required orally, n = 32
Outcomes Episodes, frequency and severity of nausea and vomiting at 24 hours; withdrawal due to
adverse effects; participant preference; episodes of drowsiness, hallucination, hypotension
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 24/32 (75%) participants re-
ceived nabilone, 24/32 (75%) participants
received prochlorperazine
Selective reporting (reporting bias) Low risk Data reported for primary outcome
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Niiranen 1985 (Continued)
Other bias Unclear risk Assumed washout period sufficient. Un-
clear if paired analysis was performed. Un-
clear if groups were balanced at baseline
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Identical appearing capsules used”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding assumed as study reported as
“double-blind” and “identical appearing
capsules used”
Orr 1981
Methods Randomised double-blind 2-period cross-over
Participants 79 people (28 men/51 women) aged 22-71 years, mean = 46 years
Tumour type: variety of neoplasms
Chemotherapy regimen: doxorubicin, cyclophosphamide, 5-fluorouracil (with
methotrexate), nitrogen mustard, imidazole carboxamide, nitrosaurea and cytosine ara-
binoside. No information on doses reported
Chemotherapy emetogenicity: high (5-fluorouracil + methotrexate low risk but only 3/
55 people)
Interventions Dronabinol 7 mg/m2 every 4 hours x 4 doses orally, n = 79
Prochlorperazine 7 mg every 4 hours x 4 doses orally, n = 79
Outcomes Nausea 24 hours post treatment and adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 55/79 (69%) participants in both groups
analysed
Selective reporting (reporting bias) Low risk Data reported for primary outcome
Other bias Unclear risk Assumed washout period sufficient. Un-
clear if paired analysis was performed. Un-
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Orr 1981 (Continued)
clear if groups were balanced at baseline
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Identical capsule used”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk States “double-blind”
Pomeroy 1986
Methods Randomised, double-blind parallel group trial
Participants 38 people (23 men/15 women) aged 21-66 years (median = 42 years)
Tumour types: ovarian cancer (11 people), testicular cancer (9 people), bronchus carci-
noma (8 people), non-Hodgkin’s lymphoma (3 people), Hodgkin’s disease (2 people),
sarcoma (2 people), breast cancer (1 person), melanoma (1 person), nephroblastoma (1
person)
Chemotherapy regimens: cisplatin (10 people); cisplatin and treosulphan (7 people)
; cisplatin, vincristine, methotrexate and bleomycin (4 people), cisplatin, actinomycin
D and etoposide (2 people); cisplatin, vinblastine and bleomycin (2 people); cisplatin
and vindesine (1 person); adriamycin, bleomycin, vincristine and DTIC (2 people);
adriamycin, vincristine and cyclophosphamide (2 people); adriamycin, vincristine, cy-
clophosphamide and prednisone (2 people); adriamycin, vincristine and etoposide (1
person); ifosfamide (2 people); vincristine, methotrexate and 5-fluorouracil (1 person);
vindesine, DTIC and 1-(2-chloroethyl)3-cyclohexyl-1-nitrosurea (CCNU) (1 person).
No information on doses reported
Chemotherapy emetogenicity: high
Interventions Nabilone 1 mg 3 times daily x 2 cycles orally, n = 19
Domperidone 20 mg 3 times daily x 2 cycles orally, n = 19
Outcomes Episodes of vomiting daily, withdrawal due to adverse effects, lack of efficacy, episodes
of drowsiness, dizziness, hypotension, euphoria
Notes 2 cycles of chemotherapy evaluated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
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Pomeroy 1986 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 32/38 (84%) participants re-
ceived nabilone, 33/38 (87%) participants
received domperidone
Selective reporting (reporting bias) Low risk Data reported for primary outcome
Other bias Unclear risk Unclear if groups were balanced at baseline
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Identical capsules used”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding assumed as study reported as
“double-blind” and “identical capsules
used”
Sallan 1975a
Methods Randomised, double-blind, 2-period cross-over study
Participants 22 people (10 men/12 women) aged 18-76 years (median = 29.5 years)
Tumour types: variety of neoplasms
Chemotherapy regimen: adriamycin, 5-azacytidine, nitrogenmustard, imidazole carbox-
amide, procarbazine, high-dose cyclophosphamide or high-dose methotrexate or com-
binations. No information on doses reported
Chemotherapy emetogenicity: unable to classify
Interventions Dronabinol 15 mg, later changed to 10 mg/m2, every 4 hours x 3 doses orally, n = 33
Placebo, n = 33
Outcomes Episodes of nausea and vomiting on day after treatment, withdrawal due to adverse
effects, episodes of feeling high, somnolence, paranoia, hallucination
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 20/33 (61%) participants received THC,
22/33 (67%) participants received placebo
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Sallan 1975a (Continued)
Selective reporting (reporting bias) Low risk Data reported for primary outcome
Other bias Unclear risk Assumed washout period sufficient. Un-
clear if paired analysis was performed. Un-
clear if groups were balanced at baseline
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Identical gelatin capsules used”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding assumed as study reported as
“double-blind” and “identical gelatin cap-
sules used”
Steele 1980
Methods Randomised, double-blind, 2-period cross-over study
Participants 55 people aged 19-65 years
Tumour types: not reported
Chemotherapy regimen: high-dose cis-dichlorodiammineplatinum 120 mg/m2 ± vinde-
sine 3 mg/m2 every 4-6 weeks; low-dose cis-dichlorodiammineplatinum 60 mg/m2 ±
vindesine 3 mg/m2, every 4-6 weeks; low-dose cis-dichlorodiammineplatinum 60 mg/
m2 ± adriamycin 45 mg/m2 every 3-4 weeks; mechlorethamine 6 mg/m2 + vincristine
1.4 mg/m2 + procarbazine orally x 14 days 100 mg/m2 every 4 weeks days 1-8; strep-
tozotocin 500 mg/m2 every week; actinomycin D 1 mg/m2 ± vinblastine 4 mg/m2 +
chlorambucil orally x 14 days 4 mg/m2 or 0.15 mg/kg every 3-4 weeks; DTIC 800 mg/
m2 ± cyclophosphamide orally x 14 days 100 mg/m2 every 4 weeks. All drugs IV unless
otherwise stated
Chemotherapy emetogenicity: high
Interventions Nabilone 2 mg every 12 hours x 3-5 doses orally, n = 55
Prochlorperazine 10 mg every 12 hours x 3-5 doses orally, n = 55
Outcomes Episodes of nausea and vomiting during 24 hours; withdrawal due to adverse effects;
lack of efficacy, episodes of somnolence, dizziness, feeling high, postural hypotension,
dysphoria, hallucination
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
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Steele 1980 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk 37/55 (67%) participants re-
ceived nabilone, 37/55 (67%) participants
received prochlorperazine
Selective reporting (reporting bias) Low risk Data reported for primary outcome
Other bias Unclear risk Assumed washout period sufficient. Un-
clear if paired analysis was performed. Un-
clear if groups were balanced at baseline
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported as “double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding assumed as study reported as
“double-blind”
Ungerleider 1982
Methods Randomised, double-blind, 2-period cross-over study
Participants 214 people (107 men/107 women) aged 18-82 years (median = 47 years)
Tumour types: “wide variety of neoplasms”
Chemotherapy regimens: antibiotics (70 people), nitrosoureas (21 people), alkylating
agents (119 people), antimetabolites (82 people), vinca-alkaloids (60 people), hormones
(13 people), miscellaneous (33 people) and combinations. Rated as high for 66% of
people, moderate for 27% of people or low for 7% of people emetic potential
Chemotherapy emetogenicity: unable to classify - unknown combinations
Interventions Dronabinol 7.5 mg for < 1.4/m2, 10 mg for 1.4-1.8 m2 or 12.5 mg for > 1.8 m2 orally,
n = 214
Prochlorperazine 10 mg 1 hour prior to chemotherapy, then every 4 hours x 4 doses per
day x all chemotherapy days orally, n = 214
Outcomes Episodes of nausea and vomiting during 24 hours; withdrawal due to adverse effects;
episodes of sedation, depression, feeling high
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers
53Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ungerleider 1982 (Continued)
Allocation concealment (selection bias) Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk 172/214 (80%) participants received
THC, 181/214 (85%) received prochlor-
perazine
Selective reporting (reporting bias) Low risk Data reported for primary outcome
Other bias Low risk Washout period 1-3 weeks. Paired analysis
was performed. Groups were balanced at
baseline
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported as “double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding assumed as study reported as
“double-blind”
Wada 1982
Methods Randomised, double-blind, 2-period cross-over trial
Participants 114 people (47 men/67 women) aged 18-81 years (median = 57 years)
Tumour types: lung cancer (23 people), breast cancer (18 people), ovarian cancer (16 peo-
ple), lymphoma (including Hodgkin’s) (12 people), colonic cancer (7 people), prostatic
cancer (5 people), adenocarcinoma (5 people), bladder cancer (3 people), melanoma (3
people), pancreatic cancer (3 people), oesophageal cancer (3 people), stomach cancer (3
people), sarcoma (2 people), testicular cancer (2 people), others (9 people)
Chemotherapy regimens: adriamycin (66 people), carmustine (2 people), bleomycin (7
people), cisplatinum (40 people), cytoxan (46 people), dactinomycin (1 person), DTIC
(7 people), 5-fluorouracil (29 people), mustine (4 people), MCCNU (6 people), mel-
phalan (1 person), methotrexate (14 people), mitomycin (17 person), procarbazine (7
people), streptozotocin (1 person), tamoxifen (1 person), vinblastine (5 person), vin-
cristine (16 people), VP-16 (1 person)
Interventions Nabilone 2 mg night prior and 1-3 hours before chemotherapy and then every 12 hours
orally, n = 114
Placebo, n = 114
Outcomes Episodes of nausea and vomiting during 24 hours; withdrawal due to adverse effects;
lack of efficacy; progressive disease; death; participant preference; episodes of dizziness,
drowsiness, euphoria, dysphoria, hypotension, hallucination
Notes
Risk of bias
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Wada 1982 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 84/114 (74%)participants completed both
the courses, 92/114 (81%) participants
were evaluable for efficacy
Selective reporting (reporting bias) Low risk Data reported for primary outcome
Other bias Unclear risk Assumed washout period sufficient. Un-
clear if paired analysis was performed. Un-
clear if groups were balanced at baseline
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported as “double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding assumed as study reported as
“double-blind”
DTIC: 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide; HN2: ; IM: intramuscular; IV: intravenous; MCCNU: methyl lomus-
tine; n: number; THC: delta-9-tetrahydrocannabinol.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aapro 1981 Not a primary study - editorial
Allan 1987 Not a primary study - review
Anderson 1981 Not a primary study - review
Artim 1983 Participants received chemotherapy and radiotherapy
Bateman 1982 Not a primary study - letter
Ben 2006 Not a primary study - review
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(Continued)
Biedrzycki 2007 Not a primary study - conference presentation
Broder 1982 Lacks data - abstract of preliminary findings, participant age and characteristics not reported
Carey 1983 Not a primary study - review
Chan 1987 Randomised controlled trial involving children
Chang 1979b Duplicate of Chang 1979a
Citron 1985 Cross route comparison of intramuscular versus oral cannabinoid
Cocchetto 1981 Not a primary study - review
Colls 1980a Letter - lacks detail on study methods, participant groups, control intervention and results
Colls 1980b Did not report data for primary outcome, measurement of nausea and vomiting using a non-validated
measure. No details on participants reported
Cone 1982 Not randomised - single-arm study
Costa 2007 Not a primary study - review
Cotter 2009 Not a primary study - review
Cronin 1981 Not randomised - single-arm cross-over study
Croxford 2003 Not a primary study - review
Cunningham 1985 Control group was cannabinoid monotherapy and not conventional anti-emetic
Cunningham 1988 Sub-therapeutic dose of prochlorperazine used
Dalzell 1986 Randomised controlled trial involving children
Darmani 2010 Not a primary study - review
Davis 2007 Not a primary study - review
Davis 2008 Not a primary study - review
Devine 1987 Not randomised - single-arm cross-over study
Dodds 1985 Not a primary study - review from thesis
Dow 1984 Not a primary study - letter
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(Continued)
Duran 2010 Not an approved formulation of delta-9-tetrahydrocannabinol
Ekert 1979 Randomised controlled trial involved children not adults
Ettinger 2007 Not a primary study - clinical practice guidelines
Feyer 2011 Not a primary study - review
Fiore 1984 Not a primary study - review
Fox 1979 Not a primary study - letter
Galal 2009 Not a primary study - review
Gallego 1984 Not a primary study - review
Gerhartz 1983 Not randomised - single-arm study
Gerra 2010 Not a primary study - review
Goodman 1997 Not a primary study - review
Gorter 1999 Not randomised
Grunberg 1989 Not a primary study - review
Guzman 2003 Not a primary study - review
Heim 1984 Evaluates a non-approved formulation of delta-9-tetrahydrocannabinol
Herrstedt 1998 Not a primary study - review
Herrstedt 2008 Not a primary study - review
Higi 1982 Pilot study
Hiller 1984 Not a primary study - review
Hutcheon 1983 Evaluates a non-approved formulation of delta-9-tetrahydrocannabinol
Jordan 2007 Not a primary study - review
Jordan 2011 Not a primary study - review guideline
Kearsley 1985 Not a primary study - review
Kenny 1982 Non-randomised single-arm study
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(Continued)
Kluin-Nelemans 1981a Duplicate to included
Kluin-Nelemans 1981b Not randomised. Abstract with scant details of methods reported
Krasnow 1991 Not a primary study - review
Kreutz 2007 Not a primary study - review
Lane 1989 Duplicate Lane 1991
Lane 1990 Duplicate data. Single-centre study included in Lane 1991
Laszlo 1982 Not a primary study - review
Levitt 1981 Evaluates ophthalmological outcomes. Nausea and vomiting not evaluated
Levitt 1984 Cross-route comparison of oral versus smoked cannabis
Lohr 2008 Not a primary study - review
Long 1982 Preliminary data presented
Machado 2008 Not a primary study - systematic review and meta-analysis
Mechoulam 1978 Not a primary study - drug development
Mechoulam 1999 Not a primary study - review
Mechoulam 2001 Not a primary study - review
Meiri 2007 Not acute nausea and vomiting but evaluating delayed nausea and vomiting
Murakami 1986 Not a primary study - review
Musty 2001 Not a primary study - review
Nagy 1978 Scanty data in an abstract - no extractable data
Navari 2009a Not a primary study - review
Navari 2009b Not a primary study - review
Niederle 1986 Evaluates a non-eligible anti-emetic (alizapride)
Niiranen 1987 Control group was cannabinoid monotherapy and not conventional anti-emetic
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(Continued)
Nyman 1982 Not a primary study - review
Orr 1980 Duplicate of Orr 1981
Penta 1981 Not a primary study - review
Perwitasari 2011 Not a primary study - review
Phillips 2010 Not a primary study - review
Plasse 1991 Not a primary study - expert opinion
Porta 2002 Not a primary study - review
Poster 1981 Not a primary study - review
Reynolds 2002 Not a primary study - letter
Sallan 1975b Duplicate study of Sallan 1975a
Sallan 1980 Participants aged 9-70 years; number or percent of children included not reported
Schuette 1985 Duplicate study reported in Niederle 1986
Sheidler 1984 Evaluates a non-approved formulation of delta-9-tetrahydrocannabinol
Slatkin 2007 Not a primary study - review
Smith 2007 Not a primary study - review
Stambaugh 1982 Cross-route comparison of intramuscular versus oral cannabinoid
Stambaugh 1984 Evaluates a non-approved formulation of delta-9-tetrahydrocannabinol
Steele 1979 Duplicate study reported in Steele 1980
Stewart 1990 Not a primary study - review
Stuart 1982 Not randomised - single-arm study
Stuart-Harris 1983 Not randomised
Sweet 1980 Not a primary study - letter
Toth 2008 Not a primary study - review
Tramer 2001 Not a primary study - review
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(Continued)
Ungerleider 1985 Sub-group analysis of study reported in Ungerleider 1982
Venner 1986 Preliminary results - ongoing study
Vincent 1983 Not a primary study - review
Voth 1997 Not a primary study - review
Wang 2008 Not a primary study - review
Ward 1985 Not a primary study - drug evaluation
Ware 2008 Not a primary study - review
Zuardi 2008 Not a primary study - review
Characteristics of studies awaiting assessment [ordered by study ID]
Citron 1983
Methods Double-blind, randomised, crossover study
Participants People reciveing chemotherapy
Interventions IM levonantradol, a synthetic cannabinoid, given at a dose of 1 mg every 4 hours versus oral delta-9-tetrahydro-
cannabinol (THC) given at a dose of 15 mg every 4 hours
Outcomes Nausea, emetic episodes
Notes
Earhart 1983
Methods RCT
Participants Cancer patients receiving cisplatin chemotherapy
Interventions Evonantradol versus prochlorperazine as parenteral antiemetics
Outcomes Nausea and vomiting
Notes
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Jhangiani 2005
Methods Double-blind, placebo-controlled study
Participants Patients receiving moderately to highly emetogenic chemotherapy
Interventions Dronabinol alone or in combination with ondansetron versus ondansetron alone
Outcomes Nausea and vomiting intensity
Notes
Neidhart 1981
Methods A prospective, randomized and double-blinded trial
Participants All patients are receiving chemotherapeutic agents known to induce severe vomiting
Interventions Effects of delta-9-tetrahydrocannabinol and haloperidol
Outcomes Nausea and vomiting
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Cannabinoid versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Absence of nausea 2 96 Risk Ratio (IV, Random, 95% CI) 2.0 [0.19, 20.97]
2 Absence of vomiting 3 168 Risk Ratio (IV, Random, 95% CI) 5.69 [2.56, 12.64]
2.1 Nabilone 1 72 Risk Ratio (IV, Random, 95% CI) 7.25 [2.84, 18.52]
2.2 Dronabinol 2 96 Risk Ratio (IV, Random, 95% CI) 3.0 [0.65, 13.76]
3 Absence of nausea and vomiting 3 288 Risk Ratio (IV, Random, 95% CI) 2.86 [1.76, 4.65]
3.1 Cannabis naive 1 75 Risk Ratio (IV, Random, 95% CI) 2.23 [1.04, 4.78]
3.2 Prior cannabis use 2 213 Risk Ratio (IV, Random, 95% CI) 3.40 [1.80, 6.39]
4 Depression 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
5 Dysphoria 2 96 Risk Ratio (IV, Random, 95% CI) 9.00 [0.50, 160.59]
6 ’Feeling high’ 3 137 Risk Ratio (IV, Random, 95% CI) 31.10 [6.37, 151.85]
7 Paranoia 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
8 Sedation 2 139 Risk Ratio (IV, Random, 95% CI) 4.47 [0.35, 57.81]
9 Participant preference 2 256 Risk Ratio (IV, Random, 95% CI) 4.82 [1.74, 13.36]
10 Withdrawal for any reason 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
11 Withdrawal due to adverse
event
2 276 Risk Ratio (IV, Random, 95% CI) 6.85 [1.96, 23.99]
12 Withdrawal due to lack of
efficacy
1 Risk Ratio (IV, Random, 95% CI) Subtotals only
Comparison 2. Cannabinoid versus other anti-emetic agent
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Absence of nausea 5 258 Risk Ratio (IV, Random, 95% CI) 1.46 [0.67, 3.15]
1.1 Prochlorperazine 5 258 Risk Ratio (IV, Random, 95% CI) 1.46 [0.67, 3.15]
2 Absence of nausea (subgroup
analysis 2)
5 Risk Ratio (IV, Random, 95% CI) Subtotals only
2.1 Nabilone 3 141 Risk Ratio (IV, Random, 95% CI) 1.41 [0.33, 6.03]
2.2 Dronabinol 2 117 Risk Ratio (IV, Random, 95% CI) 2.38 [0.21, 26.91]
3 Absence of vomiting 4 209 Risk Ratio (IV, Random, 95% CI) 1.11 [0.86, 1.44]
3.1 Prochlorperazine 4 209 Risk Ratio (IV, Random, 95% CI) 1.11 [0.86, 1.44]
4 Absence of vomiting (subgroup
analysis 2)
4 Risk Ratio (IV, Random, 95% CI) Subtotals only
4.1 Nabilone 2 93 Risk Ratio (IV, Random, 95% CI) 1.55 [0.39, 6.24]
4.2 Dronabinol 2 116 Risk Ratio (IV, Random, 95% CI) 1.05 [0.64, 1.71]
5 Absence of nausea and vomiting 4 414 Risk Ratio (IV, Random, 95% CI) 2.00 [0.74, 5.38]
5.1 Prochlorperazine 4 414 Risk Ratio (IV, Random, 95% CI) 2.00 [0.74, 5.38]
6 Absence of nausea and vomiting
(subgroup analysis 1)
4 Risk Ratio (IV, Random, 95% CI) Subtotals only
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6.1 Cannabis naive 2 116 Risk Ratio (IV, Random, 95% CI) 1.10 [0.70, 1.72]
6.2 Prior cannabis use 2 298 Risk Ratio (IV, Random, 95% CI) 17.98 [2.44, 132.43]
7 Absence of nausea and vomiting
(subgroup analysis 2)
4 Risk Ratio (IV, Random, 95% CI) Subtotals only
7.1 Nabilone 1 226 Risk Ratio (IV, Random, 95% CI) 17.0 [0.99, 291.06]
7.2 Dronabinol 3 188 Risk Ratio (IV, Random, 95% CI) 1.44 [0.62, 3.31]
8 Dizziness 9 743 Risk Ratio (IV, Random, 95% CI) 2.54 [1.91, 3.37]
8.1 Domperidone 1 38 Risk Ratio (IV, Random, 95% CI) 2.75 [1.06, 7.12]
8.2 Prochlorperazine 7 675 Risk Ratio (IV, Random, 95% CI) 2.36 [1.82, 3.07]
8.3 Metoclopramide 1 30 Risk Ratio (IV, Random, 95% CI) 12.0 [1.78, 81.06]
9 Dysphoria 3 192 Risk Ratio (IV, Random, 95% CI) 7.17 [1.33, 38.84]
9.1 Prochloperazine 3 192 Risk Ratio (IV, Random, 95% CI) 7.17 [1.33, 38.84]
10 Euphoria 4 358 Risk Ratio (IV, Random, 95% CI) 8.89 [2.05, 38.63]
10.1 Domperidone 1 38 Risk Ratio (IV, Random, 95% CI) 5.0 [0.26, 97.70]
10.2 Prochlorperazine 2 280 Risk Ratio (IV, Random, 95% CI) 17.97 [2.42, 133.37]
10.3 Chlorpromazine 1 40 Risk Ratio (IV, Random, 95% CI) 3.0 [0.13, 69.52]
11 ’Feeling high’ 5 419 Risk Ratio (IV, Random, 95% CI) 5.90 [3.42, 10.17]
11.1 Prochlorperazine 4 389 Risk Ratio (IV, Random, 95% CI) 6.18 [3.52, 10.85]
11.2 Metoclopramide 1 30 Risk Ratio (IV, Random, 95% CI) 3.0 [0.35, 25.68]
12 Hallucinations 2 144 Risk Ratio (IV, Random, 95% CI) 5.39 [0.66, 43.68]
12.1 Prochlorperazine 2 144 Risk Ratio (IV, Random, 95% CI) 5.39 [0.66, 43.68]
13 Postural hypotension 6 413 Risk Ratio (IV, Random, 95% CI) 2.40 [0.88, 6.53]
13.1 Domperidone 1 38 Risk Ratio (IV, Random, 95% CI) 4.0 [0.49, 32.57]
13.2 Prochlorperazine 3 305 Risk Ratio (IV, Random, 95% CI) 1.22 [0.52, 2.89]
13.3 Metoclopramide 1 30 Risk Ratio (IV, Random, 95% CI) 17.0 [1.07, 270.41]
13.4 Chlorpromazine 1 40 Risk Ratio (IV, Random, 95% CI) 7.0 [0.95, 51.80]
14 Paranoia 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
14.1 Prochlorperazine 1 42 Risk Ratio (IV, Random, 95% CI) 3.0 [0.13, 69.70]
15 Sedation 11 1055 Risk Ratio (IV, Random, 95% CI) 1.33 [1.08, 1.64]
15.1 Domperidone 1 38 Risk Ratio (IV, Random, 95% CI) 1.22 [0.66, 2.25]
15.2 Prochlorperazine 8 947 Risk Ratio (IV, Random, 95% CI) 1.44 [1.18, 1.76]
15.3 Metoclopramide 1 30 Risk Ratio (IV, Random, 95% CI) 0.93 [0.73, 1.18]
15.4 Chlorpromazine 1 40 Risk Ratio (IV, Random, 95% CI) 1.71 [0.85, 3.44]
16 Depression 3 317 Risk Ratio (IV, Random, 95% CI) 0.81 [0.51, 1.28]
16.1 Prochlorperazine 3 317 Risk Ratio (IV, Random, 95% CI) 0.81 [0.51, 1.28]
17 Participant preference 9 799 Risk Ratio (IV, Random, 95% CI) 2.76 [1.88, 4.03]
17.1 Prochlorperazine 7 695 Risk Ratio (IV, Random, 95% CI) 3.24 [2.23, 4.72]
17.2 Metoclopramide 1 64 Risk Ratio (IV, Random, 95% CI) 1.2 [0.61, 2.37]
17.3 Chlorpromazine 1 40 Risk Ratio (IV, Random, 95% CI) 2.0 [0.83, 4.81]
18 Withdrawal for any reason 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
18.1 Prochlorperazine 1 42 Risk Ratio (IV, Random, 95% CI) 3.5 [1.38, 8.89]
19 Withdrawal due to adverse
event
6 740 Risk Ratio (IV, Random, 95% CI) 3.16 [1.26, 7.93]
19.1 Domperidone 1 76 Risk Ratio (IV, Random, 95% CI) 3.0 [0.13, 71.40]
19.2 Prochlorperazine 5 664 Risk Ratio (IV, Random, 95% CI) 3.90 [1.25, 12.20]
20 Withdrawal due to lack of
efficacy
2 118 Risk Ratio (IV, Random, 95% CI) 0.97 [0.04, 20.93]
20.1 Domperidone 1 76 Risk Ratio (IV, Random, 95% CI) 0.14 [0.01, 2.67]
20.2 Prochlorperazine 1 42 Risk Ratio (IV, Random, 95% CI) 3.5 [1.38, 8.89]
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Comparison 3. Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Absence of nausea 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
2 Absence of vomiting 2 89 Risk Ratio (IV, Random, 95% CI) 1.47 [0.69, 3.13]
3 Absence of nausea and vomiting 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
4 Depression 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
5 Dizziness 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
6 Dysphoria 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
7 Paranoia 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
8 Sedation 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
9 Withdrawal for any reason 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
10 Withdrawal due to adverse
event
2 105 Risk Ratio (IV, Random, 95% CI) 6.97 [0.88, 55.19]
11 Withdrawal due to lack of
efficacy
1 Risk Ratio (IV, Random, 95% CI) Subtotals only
Analysis 1.1. Comparison 1 Cannabinoid versus placebo, Outcome 1 Absence of nausea.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 1 Cannabinoid versus placebo
Outcome: 1 Absence of nausea
Study or subgroup Cannabinoid Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Chang 1979a 2/32 1/32 100.0 % 2.00 [ 0.19, 20.97 ]
Chang 1981 0/16 0/16 Not estimable
Total (95% CI) 48 48 100.0 % 2.00 [ 0.19, 20.97 ]
Total events: 2 (Cannabinoid), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours placebo Favours cannabinoid
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Analysis 1.2. Comparison 1 Cannabinoid versus placebo, Outcome 2 Absence of vomiting.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 1 Cannabinoid versus placebo
Outcome: 2 Absence of vomiting
Study or subgroup Cannabinoid Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Nabilone
Levitt 1982 29/36 4/36 72.5 % 7.25 [ 2.84, 18.52 ]
Subtotal (95% CI) 36 36 72.5 % 7.25 [ 2.84, 18.52 ]
Total events: 29 (Cannabinoid), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.14 (P = 0.000035)
2 Dronabinol
Chang 1979a 6/32 2/32 27.5 % 3.00 [ 0.65, 13.76 ]
Chang 1981 0/16 0/16 Not estimable
Subtotal (95% CI) 48 48 27.5 % 3.00 [ 0.65, 13.76 ]
Total events: 6 (Cannabinoid), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
Total (95% CI) 84 84 100.0 % 5.69 [ 2.56, 12.64 ]
Total events: 35 (Cannabinoid), 6 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.93, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 4.27 (P = 0.000020)
Test for subgroup differences: Chi2 = 0.93, df = 1 (P = 0.33), I2 =0.0%
0.05 0.2 1 5 20
Favours placebo Favours cannabinoid
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Analysis 1.3. Comparison 1 Cannabinoid versus placebo, Outcome 3 Absence of nausea and vomiting.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 1 Cannabinoid versus placebo
Outcome: 3 Absence of nausea and vomiting
Study or subgroup Cannabinoid Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Cannabis naive
Frytak 1979 16/38 7/37 40.6 % 2.23 [ 1.04, 4.78 ]
Subtotal (95% CI) 38 37 40.6 % 2.23 [ 1.04, 4.78 ]
Total events: 16 (Cannabinoid), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.05 (P = 0.040)
2 Prior cannabis use
Sallan 1975a 5/15 0/14 3.0 % 10.31 [ 0.62, 170.96 ]
Wada 1982 32/92 10/92 56.4 % 3.20 [ 1.67, 6.12 ]
Subtotal (95% CI) 107 106 59.4 % 3.40 [ 1.80, 6.39 ]
Total events: 37 (Cannabinoid), 10 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.63, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 3.79 (P = 0.00015)
Total (95% CI) 145 143 100.0 % 2.86 [ 1.76, 4.65 ]
Total events: 53 (Cannabinoid), 17 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.33, df = 2 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 4.23 (P = 0.000023)
Test for subgroup differences: Chi2 = 0.70, df = 1 (P = 0.40), I2 =0.0%
0.05 0.2 1 5 20
Favours placebo Favours cannabinoid
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Analysis 1.4. Comparison 1 Cannabinoid versus placebo, Outcome 4 Depression.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 1 Cannabinoid versus placebo
Outcome: 4 Depression
Study or subgroup Cannabinoid Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Chang 1979a 1/7 0/9 3.75 [ 0.18, 80.19 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 1 (Cannabinoid), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.05 0.2 1 5 20
Favours cannabinoid Favours placebo
Analysis 1.5. Comparison 1 Cannabinoid versus placebo, Outcome 5 Dysphoria.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 1 Cannabinoid versus placebo
Outcome: 5 Dysphoria
Study or subgroup Cannabinoid Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Chang 1979a 4/32 0/32 100.0 % 9.00 [ 0.50, 160.59 ]
Chang 1981 0/16 0/16 Not estimable
Total (95% CI) 48 48 100.0 % 9.00 [ 0.50, 160.59 ]
Total events: 4 (Cannabinoid), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours cannabinoid Favours placebo
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Analysis 1.6. Comparison 1 Cannabinoid versus placebo, Outcome 6 ’Feeling high’.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 1 Cannabinoid versus placebo
Outcome: 6 ’Feeling high’
Study or subgroup Cannabinoid Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Chang 1981 14/16 0/16 33.5 % 29.00 [ 1.88, 448.17 ]
Frytak 1979 22/38 0/37 32.9 % 43.85 [ 2.76, 697.35 ]
Sallan 1975a 13/16 0/14 33.6 % 23.82 [ 1.54, 367.46 ]
Total (95% CI) 70 67 100.0 % 31.10 [ 6.37, 151.85 ]
Total events: 49 (Cannabinoid), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 2 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 4.25 (P = 0.000022)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours cannabinoid Favours placebo
Analysis 1.7. Comparison 1 Cannabinoid versus placebo, Outcome 7 Paranoia.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 1 Cannabinoid versus placebo
Outcome: 7 Paranoia
Study or subgroup Cannabinoid Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Chang 1979a 1/32 0/32 3.00 [ 0.13, 71.00 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 1 (Cannabinoid), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.05 0.2 1 5 20
Favours cannabinoid Favours placebo
68Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.8. Comparison 1 Cannabinoid versus placebo, Outcome 8 Sedation.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 1 Cannabinoid versus placebo
Outcome: 8 Sedation
Study or subgroup Cannabinoid Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Chang 1979a 12/32 0/32 36.5 % 25.00 [ 1.54, 405.08 ]
Frytak 1979 29/38 17/37 63.5 % 1.66 [ 1.12, 2.46 ]
Total (95% CI) 70 69 100.0 % 4.47 [ 0.35, 57.81 ]
Total events: 41 (Cannabinoid), 17 (Placebo)
Heterogeneity: Tau2 = 2.65; Chi2 = 3.57, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours cannabinoid Favours placebo
Analysis 1.9. Comparison 1 Cannabinoid versus placebo, Outcome 9 Participant preference.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 1 Cannabinoid versus placebo
Outcome: 9 Participant preference
Study or subgroup Cannabinoid Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Levitt 1982 28/36 3/36 38.2 % 9.33 [ 3.11, 27.97 ]
Wada 1982 64/92 20/92 61.8 % 3.20 [ 2.12, 4.82 ]
Total (95% CI) 128 128 100.0 % 4.82 [ 1.74, 13.36 ]
Total events: 92 (Cannabinoid), 23 (Placebo)
Heterogeneity: Tau2 = 0.39; Chi2 = 3.21, df = 1 (P = 0.07); I2 =69%
Test for overall effect: Z = 3.02 (P = 0.0025)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours placebo Favours cannabinoid
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Analysis 1.10. Comparison 1 Cannabinoid versus placebo, Outcome 10 Withdrawal for any reason.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 1 Cannabinoid versus placebo
Outcome: 10 Withdrawal for any reason
Study or subgroup Cannabinoid Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Chang 1981 0/17 1/16 0.31 [ 0.01, 7.21 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (Cannabinoid), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours cannabinoid Favours placebo
Analysis 1.11. Comparison 1 Cannabinoid versus placebo, Outcome 11 Withdrawal due to adverse event.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 1 Cannabinoid versus placebo
Outcome: 11 Withdrawal due to adverse event
Study or subgroup Cannabinoid Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Jones 1982 11/24 2/24 80.5 % 5.50 [ 1.36, 22.22 ]
Wada 1982 8/114 0/114 19.5 % 17.00 [ 0.99, 291.09 ]
Total (95% CI) 138 138 100.0 % 6.85 [ 1.96, 23.99 ]
Total events: 19 (Cannabinoid), 2 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.49, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 3.01 (P = 0.0026)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours cannabinoid Favours placebo
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Analysis 1.12. Comparison 1 Cannabinoid versus placebo, Outcome 12 Withdrawal due to lack of efficacy.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 1 Cannabinoid versus placebo
Outcome: 12 Withdrawal due to lack of efficacy
Study or subgroup Cannabinoid Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Wada 1982 0/114 9/114 0.05 [ 0.00, 0.89 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (Cannabinoid), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours cannabinoid Favours placebo
Analysis 2.1. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 1 Absence of nausea.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 2 Cannabinoid versus other anti-emetic agent
Outcome: 1 Absence of nausea
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Prochlorperazine
Ahmedzai 1983 19/27 11/30 38.4 % 1.92 [ 1.13, 3.26 ]
Frytak 1979 17/42 16/38 38.6 % 0.96 [ 0.57, 1.62 ]
Johansson 1982 3/18 0/18 6.2 % 7.00 [ 0.39, 126.48 ]
Lane 1991 5/17 0/20 6.4 % 12.83 [ 0.76, 216.55 ]
Niiranen 1985 1/24 4/24 10.3 % 0.25 [ 0.03, 2.08 ]
Total (95% CI) 128 130 100.0 % 1.46 [ 0.67, 3.15 ]
Total events: 45 (Cannabinoid), 31 (Control)
Heterogeneity: Tau2 = 0.33; Chi2 = 9.42, df = 4 (P = 0.05); I2 =58%
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours control Favours cannabinoid
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Analysis 2.2. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 2 Absence of nausea
(subgroup analysis 2).
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 2 Cannabinoid versus other anti-emetic agent
Outcome: 2 Absence of nausea (subgroup analysis 2)
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Nabilone
Ahmedzai 1983 19/27 11/30 55.8 % 1.92 [ 1.13, 3.26 ]
Johansson 1982 3/18 0/18 17.8 % 7.00 [ 0.39, 126.48 ]
Niiranen 1985 1/24 4/24 26.4 % 0.25 [ 0.03, 2.08 ]
Subtotal (95% CI) 69 72 100.0 % 1.41 [ 0.33, 6.03 ]
Total events: 23 (Cannabinoid), 15 (Control)
Heterogeneity: Tau2 = 0.91; Chi2 = 4.24, df = 2 (P = 0.12); I2 =53%
Test for overall effect: Z = 0.46 (P = 0.64)
2 Dronabinol
Frytak 1979 17/42 16/38 64.9 % 0.96 [ 0.57, 1.62 ]
Lane 1991 5/17 0/20 35.1 % 12.83 [ 0.76, 216.55 ]
Subtotal (95% CI) 59 58 100.0 % 2.38 [ 0.21, 26.91 ]
Total events: 22 (Cannabinoid), 16 (Control)
Heterogeneity: Tau2 = 2.28; Chi2 = 3.12, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Chi2 = 0.13, df = 1 (P = 0.72), I2 =0.0%
0.01 0.1 1 10 100
Favours cannabinoid Favours control
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Analysis 2.3. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 3 Absence of vomiting.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 2 Cannabinoid versus other anti-emetic agent
Outcome: 3 Absence of vomiting
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Prochlorperazine
Ahmedzai 1983 21/27 21/30 70.8 % 1.11 [ 0.82, 1.51 ]
Frytak 1979 17/38 18/41 27.7 % 1.02 [ 0.62, 1.67 ]
Johansson 1982 3/18 0/18 0.8 % 7.00 [ 0.39, 126.48 ]
Lane 1991 1/17 0/20 0.7 % 3.50 [ 0.15, 80.71 ]
Total (95% CI) 100 109 100.0 % 1.11 [ 0.86, 1.44 ]
Total events: 42 (Cannabinoid), 39 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.18, df = 3 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.43)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours control Favours cannabinoid
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Analysis 2.4. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 4 Absence of vomiting
(subgroup analysis 2).
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 2 Cannabinoid versus other anti-emetic agent
Outcome: 4 Absence of vomiting (subgroup analysis 2)
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Nabilone
Ahmedzai 1983 21/27 21/30 81.8 % 1.11 [ 0.82, 1.51 ]
Johansson 1982 3/18 0/18 18.2 % 7.00 [ 0.39, 126.48 ]
Subtotal (95% CI) 45 48 100.0 % 1.55 [ 0.39, 6.24 ]
Total events: 24 (Cannabinoid), 21 (Control)
Heterogeneity: Tau2 = 0.59; Chi2 = 1.54, df = 1 (P = 0.22); I2 =35%
Test for overall effect: Z = 0.62 (P = 0.54)
2 Dronabinol
Frytak 1979 17/38 18/41 97.6 % 1.02 [ 0.62, 1.67 ]
Lane 1991 1/17 0/20 2.4 % 3.50 [ 0.15, 80.71 ]
Subtotal (95% CI) 55 61 100.0 % 1.05 [ 0.64, 1.71 ]
Total events: 18 (Cannabinoid), 18 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.58, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Chi2 = 0.27, df = 1 (P = 0.60), I2 =0.0%
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Analysis 2.5. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 5 Absence of nausea and
vomiting.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 2 Cannabinoid versus other anti-emetic agent
Outcome: 5 Absence of nausea and vomiting
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Prochlorperazine
Frytak 1979 16/38 17/41 44.2 % 1.02 [ 0.60, 1.71 ]
Herman 1979 8/113 0/113 9.8 % 17.00 [ 0.99, 291.06 ]
Lane 1991 7/17 6/20 36.1 % 1.37 [ 0.57, 3.30 ]
McCabe 1988 9/36 0/36 10.0 % 19.00 [ 1.15, 314.66 ]
Total (95% CI) 204 210 100.0 % 2.00 [ 0.74, 5.38 ]
Total events: 40 (Cannabinoid), 23 (Control)
Heterogeneity: Tau2 = 0.51; Chi2 = 7.51, df = 3 (P = 0.06); I2 =60%
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours control Favours cannabinoid
75Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.6. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 6 Absence of nausea and
vomiting (subgroup analysis 1).
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 2 Cannabinoid versus other anti-emetic agent
Outcome: 6 Absence of nausea and vomiting (subgroup analysis 1)
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Cannabis naive
Frytak 1979 16/38 17/41 74.0 % 1.02 [ 0.60, 1.71 ]
Lane 1991 7/17 6/20 26.0 % 1.37 [ 0.57, 3.30 ]
Subtotal (95% CI) 55 61 100.0 % 1.10 [ 0.70, 1.72 ]
Total events: 23 (Cannabinoid), 23 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.33, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
2 Prior cannabis use
Herman 1979 8/113 0/113 49.4 % 17.00 [ 0.99, 291.06 ]
McCabe 1988 9/36 0/36 50.6 % 19.00 [ 1.15, 314.66 ]
Subtotal (95% CI) 149 149 100.0 % 17.98 [ 2.44, 132.43 ]
Total events: 17 (Cannabinoid), 0 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 2.84 (P = 0.0046)
Test for subgroup differences: Chi2 = 7.17, df = 1 (P = 0.01), I2 =86%
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Analysis 2.7. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 7 Absence of nausea and
vomiting (subgroup analysis 2).
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 2 Cannabinoid versus other anti-emetic agent
Outcome: 7 Absence of nausea and vomiting (subgroup analysis 2)
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Nabilone
Herman 1979 8/113 0/113 100.0 % 17.00 [ 0.99, 291.06 ]
Subtotal (95% CI) 113 113 100.0 % 17.00 [ 0.99, 291.06 ]
Total events: 8 (Cannabinoid), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.051)
2 Dronabinol
Frytak 1979 16/38 17/41 53.5 % 1.02 [ 0.60, 1.71 ]
Lane 1991 7/17 6/20 38.7 % 1.37 [ 0.57, 3.30 ]
McCabe 1988 9/36 0/36 7.8 % 19.00 [ 1.15, 314.66 ]
Subtotal (95% CI) 91 97 100.0 % 1.44 [ 0.62, 3.31 ]
Total events: 32 (Cannabinoid), 23 (Control)
Heterogeneity: Tau2 = 0.27; Chi2 = 4.20, df = 2 (P = 0.12); I2 =52%
Test for overall effect: Z = 0.85 (P = 0.40)
Test for subgroup differences: Chi2 = 2.68, df = 1 (P = 0.10), I2 =63%
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Analysis 2.8. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 8 Dizziness.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 2 Cannabinoid versus other anti-emetic agent
Outcome: 8 Dizziness
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Domperidone
Pomeroy 1986 11/19 4/19 7.9 % 2.75 [ 1.06, 7.12 ]
Subtotal (95% CI) 19 19 7.9 % 2.75 [ 1.06, 7.12 ]
Total events: 11 (Cannabinoid), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.08 (P = 0.037)
2 Prochlorperazine
Ahmedzai 1983 4/28 0/26 1.0 % 8.38 [ 0.47, 148.43 ]
Einhorn 1981 60/80 30/80 37.5 % 2.00 [ 1.47, 2.73 ]
Herman 1979 78/113 34/113 37.8 % 2.29 [ 1.69, 3.12 ]
Johansson 1982 6/26 2/23 3.4 % 2.65 [ 0.59, 11.88 ]
Lane 1991 7/21 1/21 2.0 % 7.00 [ 0.94, 52.04 ]
Niiranen 1985 13/24 0/24 1.0 % 27.00 [ 1.70, 429.89 ]
Steele 1980 19/53 4/43 7.2 % 3.85 [ 1.42, 10.48 ]
Subtotal (95% CI) 345 330 90.0 % 2.36 [ 1.82, 3.07 ]
Total events: 187 (Cannabinoid), 71 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 6.84, df = 6 (P = 0.34); I2 =12%
Test for overall effect: Z = 6.42 (P < 0.00001)
3 Metoclopramide
Gralla 1984 12/15 1/15 2.1 % 12.00 [ 1.78, 81.06 ]
Subtotal (95% CI) 15 15 2.1 % 12.00 [ 1.78, 81.06 ]
Total events: 12 (Cannabinoid), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.55 (P = 0.011)
Total (95% CI) 379 364 100.0 % 2.54 [ 1.91, 3.37 ]
Total events: 210 (Cannabinoid), 76 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 9.81, df = 8 (P = 0.28); I2 =18%
Test for overall effect: Z = 6.42 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.78, df = 2 (P = 0.25), I2 =28%
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Analysis 2.9. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 9 Dysphoria.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 2 Cannabinoid versus other anti-emetic agent
Outcome: 9 Dysphoria
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Prochloperazine
Ahmedzai 1983 2/28 0/26 31.9 % 4.66 [ 0.23, 92.64 ]
Lane 1991 8/21 0/21 36.6 % 17.00 [ 1.04, 276.85 ]
Steele 1980 2/53 0/43 31.5 % 4.07 [ 0.20, 82.67 ]
Total (95% CI) 102 90 100.0 % 7.17 [ 1.33, 38.84 ]
Total events: 12 (Cannabinoid), 0 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.58, df = 2 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 2.29 (P = 0.022)
Test for subgroup differences: Not applicable
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Analysis 2.10. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 10 Euphoria.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 2 Cannabinoid versus other anti-emetic agent
Outcome: 10 Euphoria
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Domperidone
Pomeroy 1986 2/19 0/19 24.4 % 5.00 [ 0.26, 97.70 ]
Subtotal (95% CI) 19 19 24.4 % 5.00 [ 0.26, 97.70 ]
Total events: 2 (Cannabinoid), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
2 Prochlorperazine
Ahmedzai 1983 4/28 0/26 26.1 % 8.38 [ 0.47, 148.43 ]
Herman 1979 18/113 0/113 27.6 % 37.00 [ 2.26, 606.63 ]
Subtotal (95% CI) 141 139 53.7 % 17.97 [ 2.42, 133.37 ]
Total events: 22 (Cannabinoid), 0 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 2.82 (P = 0.0047)
3 Chlorpromazine
George 1983 1/20 0/20 21.9 % 3.00 [ 0.13, 69.52 ]
Subtotal (95% CI) 20 20 21.9 % 3.00 [ 0.13, 69.52 ]
Total events: 1 (Cannabinoid), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Total (95% CI) 180 178 100.0 % 8.89 [ 2.05, 38.63 ]
Total events: 25 (Cannabinoid), 0 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.60, df = 3 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 2.91 (P = 0.0036)
Test for subgroup differences: Chi2 = 1.08, df = 2 (P = 0.58), I2 =0.0%
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Analysis 2.11. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 11 ’Feeling high’.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 2 Cannabinoid versus other anti-emetic agent
Outcome: 11 ’Feeling high’
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Prochlorperazine
Ahmedzai 1983 7/28 0/26 3.7 % 13.97 [ 0.84, 232.97 ]
Einhorn 1981 40/80 6/80 46.4 % 6.67 [ 3.00, 14.84 ]
Frytak 1979 22/38 5/41 39.7 % 4.75 [ 2.00, 11.27 ]
Steele 1980 10/53 0/43 3.8 % 17.11 [ 1.03, 283.92 ]
Subtotal (95% CI) 199 190 93.6 % 6.18 [ 3.52, 10.85 ]
Total events: 79 (Cannabinoid), 11 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.22, df = 3 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 6.33 (P < 0.00001)
2 Metoclopramide
Gralla 1984 3/15 1/15 6.4 % 3.00 [ 0.35, 25.68 ]
Subtotal (95% CI) 15 15 6.4 % 3.00 [ 0.35, 25.68 ]
Total events: 3 (Cannabinoid), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Total (95% CI) 214 205 100.0 % 5.90 [ 3.42, 10.17 ]
Total events: 82 (Cannabinoid), 12 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.63, df = 4 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 6.38 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.41, df = 1 (P = 0.52), I2 =0.0%
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Analysis 2.12. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 12 Hallucinations.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 2 Cannabinoid versus other anti-emetic agent
Outcome: 12 Hallucinations
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Prochlorperazine
Niiranen 1985 3/24 0/24 51.7 % 7.00 [ 0.38, 128.61 ]
Steele 1980 2/53 0/43 48.3 % 4.07 [ 0.20, 82.67 ]
Total (95% CI) 77 67 100.0 % 5.39 [ 0.66, 43.68 ]
Total events: 5 (Cannabinoid), 0 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.58 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 2.13. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 13 Postural
hypotension.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 2 Cannabinoid versus other anti-emetic agent
Outcome: 13 Postural hypotension
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Domperidone
Pomeroy 1986 4/19 1/19 13.4 % 4.00 [ 0.49, 32.57 ]
Subtotal (95% CI) 19 19 13.4 % 4.00 [ 0.49, 32.57 ]
Total events: 4 (Cannabinoid), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.20)
2 Prochlorperazine
Einhorn 1981 70/80 70/80 32.4 % 1.00 [ 0.89, 1.12 ]
Johansson 1982 1/26 2/23 11.7 % 0.44 [ 0.04, 4.56 ]
Steele 1980 9/53 2/43 19.0 % 3.65 [ 0.83, 16.01 ]
Subtotal (95% CI) 159 146 63.1 % 1.22 [ 0.52, 2.89 ]
Total events: 80 (Cannabinoid), 74 (Control)
Heterogeneity: Tau2 = 0.29; Chi2 = 3.41, df = 2 (P = 0.18); I2 =41%
Test for overall effect: Z = 0.45 (P = 0.65)
3 Metoclopramide
Gralla 1984 8/15 0/15 9.3 % 17.00 [ 1.07, 270.41 ]
Subtotal (95% CI) 15 15 9.3 % 17.00 [ 1.07, 270.41 ]
Total events: 8 (Cannabinoid), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.045)
4 Chlorpromazine
George 1983 7/20 1/20 14.1 % 7.00 [ 0.95, 51.80 ]
Subtotal (95% CI) 20 20 14.1 % 7.00 [ 0.95, 51.80 ]
Total events: 7 (Cannabinoid), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.91 (P = 0.057)
Total (95% CI) 213 200 100.0 % 2.40 [ 0.88, 6.53 ]
Total events: 99 (Cannabinoid), 76 (Control)
Heterogeneity: Tau2 = 0.80; Chi2 = 12.62, df = 5 (P = 0.03); I2 =60%
Test for overall effect: Z = 1.71 (P = 0.086)
Test for subgroup differences: Chi2 = 5.48, df = 3 (P = 0.14), I2 =45%
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Analysis 2.14. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 14 Paranoia.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 2 Cannabinoid versus other anti-emetic agent
Outcome: 14 Paranoia
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Prochlorperazine
Lane 1991 1/21 0/21 100.0 % 3.00 [ 0.13, 69.70 ]
Subtotal (95% CI) 21 21 100.0 % 3.00 [ 0.13, 69.70 ]
Total events: 1 (Cannabinoid), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 2.15. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 15 Sedation.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 2 Cannabinoid versus other anti-emetic agent
Outcome: 15 Sedation
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Domperidone
Pomeroy 1986 11/19 9/19 7.9 % 1.22 [ 0.66, 2.25 ]
Subtotal (95% CI) 19 19 7.9 % 1.22 [ 0.66, 2.25 ]
Total events: 11 (Cannabinoid), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
2 Prochlorperazine
Ahmedzai 1983 4/28 1/26 0.9 % 3.71 [ 0.44, 31.11 ]
Frytak 1979 29/38 29/41 17.2 % 1.08 [ 0.83, 1.41 ]
Herman 1979 96/113 54/113 19.3 % 1.78 [ 1.44, 2.19 ]
Johansson 1982 1/26 0/23 0.4 % 2.67 [ 0.11, 62.42 ]
Lane 1991 4/21 3/21 2.1 % 1.33 [ 0.34, 5.24 ]
Niiranen 1985 2/24 0/24 0.5 % 5.00 [ 0.25, 98.96 ]
Steele 1980 25/53 15/43 10.1 % 1.35 [ 0.82, 2.22 ]
Ungerleider 1982 78/172 56/181 16.9 % 1.47 [ 1.12, 1.92 ]
Subtotal (95% CI) 475 472 67.5 % 1.44 [ 1.18, 1.76 ]
Total events: 239 (Cannabinoid), 158 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 10.10, df = 7 (P = 0.18); I2 =31%
Test for overall effect: Z = 3.63 (P = 0.00028)
3 Metoclopramide
Gralla 1984 13/15 14/15 18.1 % 0.93 [ 0.73, 1.18 ]
Subtotal (95% CI) 15 15 18.1 % 0.93 [ 0.73, 1.18 ]
Total events: 13 (Cannabinoid), 14 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
4 Chlorpromazine
George 1983 12/20 7/20 6.5 % 1.71 [ 0.85, 3.44 ]
Subtotal (95% CI) 20 20 6.5 % 1.71 [ 0.85, 3.44 ]
Total events: 12 (Cannabinoid), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
Total (95% CI) 529 526 100.0 % 1.33 [ 1.08, 1.64 ]
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(. . . Continued)
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Total events: 275 (Cannabinoid), 188 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 21.40, df = 10 (P = 0.02); I2 =53%
Test for overall effect: Z = 2.69 (P = 0.0071)
Test for subgroup differences: Chi2 = 8.65, df = 3 (P = 0.03), I2 =65%
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Analysis 2.16. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 16 Depression.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 2 Cannabinoid versus other anti-emetic agent
Outcome: 16 Depression
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Prochlorperazine
Herman 1979 23/113 30/113 94.7 % 0.77 [ 0.48, 1.23 ]
Johansson 1982 1/26 1/23 2.9 % 0.88 [ 0.06, 13.35 ]
Lane 1991 2/21 0/21 2.4 % 5.00 [ 0.25, 98.27 ]
Total (95% CI) 160 157 100.0 % 0.81 [ 0.51, 1.28 ]
Total events: 26 (Cannabinoid), 31 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.49, df = 2 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 2.17. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 17 Participant
preference.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 2 Cannabinoid versus other anti-emetic agent
Outcome: 17 Participant preference
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Prochlorperazine
Ahmedzai 1983 12/27 7/30 11.0 % 1.90 [ 0.88, 4.13 ]
Einhorn 1981 60/80 17/80 15.8 % 3.53 [ 2.27, 5.48 ]
Herman 1979 85/113 18/113 15.9 % 4.72 [ 3.05, 7.31 ]
Johansson 1982 13/18 3/18 7.8 % 4.33 [ 1.48, 12.66 ]
McCabe 1988 23/36 1/36 3.2 % 23.00 [ 3.28, 161.35 ]
Niiranen 1985 16/24 6/24 11.3 % 2.67 [ 1.26, 5.64 ]
Steele 1980 23/53 10/43 13.1 % 1.87 [ 1.00, 3.48 ]
Subtotal (95% CI) 351 344 78.0 % 3.24 [ 2.23, 4.72 ]
Total events: 232 (Cannabinoid), 62 (Control)
Heterogeneity: Tau2 = 0.12; Chi2 = 12.19, df = 6 (P = 0.06); I2 =51%
Test for overall effect: Z = 6.15 (P < 0.00001)
2 Metoclopramide
Crawford 1986 12/32 10/32 12.2 % 1.20 [ 0.61, 2.37 ]
Subtotal (95% CI) 32 32 12.2 % 1.20 [ 0.61, 2.37 ]
Total events: 12 (Cannabinoid), 10 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
3 Chlorpromazine
George 1983 10/20 5/20 9.7 % 2.00 [ 0.83, 4.81 ]
Subtotal (95% CI) 20 20 9.7 % 2.00 [ 0.83, 4.81 ]
Total events: 10 (Cannabinoid), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
Total (95% CI) 403 396 100.0 % 2.76 [ 1.88, 4.03 ]
Total events: 254 (Cannabinoid), 77 (Control)
Heterogeneity: Tau2 = 0.19; Chi2 = 20.67, df = 8 (P = 0.01); I2 =61%
Test for overall effect: Z = 5.21 (P < 0.00001)
Test for subgroup differences: Chi2 = 6.56, df = 2 (P = 0.04), I2 =69%
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Analysis 2.18. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 18 Withdrawal for any
reason.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 2 Cannabinoid versus other anti-emetic agent
Outcome: 18 Withdrawal for any reason
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Prochlorperazine
Lane 1991 14/21 4/21 100.0 % 3.50 [ 1.38, 8.89 ]
Subtotal (95% CI) 21 21 100.0 % 3.50 [ 1.38, 8.89 ]
Total events: 14 (Cannabinoid), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.63 (P = 0.0084)
Test for subgroup differences: Not applicable
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Analysis 2.19. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 19 Withdrawal due to
adverse event.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 2 Cannabinoid versus other anti-emetic agent
Outcome: 19 Withdrawal due to adverse event
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Domperidone
Pomeroy 1986 1/38 0/38 8.4 % 3.00 [ 0.13, 71.40 ]
Subtotal (95% CI) 38 38 8.4 % 3.00 [ 0.13, 71.40 ]
Total events: 1 (Cannabinoid), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
2 Prochlorperazine
Einhorn 1981 3/100 0/100 9.8 % 7.00 [ 0.37, 133.78 ]
Herman 1979 5/152 4/152 50.6 % 1.25 [ 0.34, 4.57 ]
Johansson 1982 4/27 0/27 10.3 % 9.00 [ 0.51, 159.43 ]
Lane 1991 10/21 0/21 11.0 % 21.00 [ 1.31, 336.75 ]
Niiranen 1985 3/32 0/32 9.9 % 7.00 [ 0.38, 130.26 ]
Subtotal (95% CI) 332 332 91.6 % 3.90 [ 1.25, 12.20 ]
Total events: 25 (Cannabinoid), 4 (Control)
Heterogeneity: Tau2 = 0.31; Chi2 = 4.83, df = 4 (P = 0.31); I2 =17%
Test for overall effect: Z = 2.34 (P = 0.019)
Total (95% CI) 370 370 100.0 % 3.16 [ 1.26, 7.93 ]
Total events: 26 (Cannabinoid), 4 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.83, df = 5 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 2.45 (P = 0.014)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
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89Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.20. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 20 Withdrawal due to
lack of efficacy.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 2 Cannabinoid versus other anti-emetic agent
Outcome: 20 Withdrawal due to lack of efficacy
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Domperidone
Pomeroy 1986 0/38 3/38 40.2 % 0.14 [ 0.01, 2.67 ]
Subtotal (95% CI) 38 38 40.2 % 0.14 [ 0.01, 2.67 ]
Total events: 0 (Cannabinoid), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
2 Prochlorperazine
Lane 1991 14/21 4/21 59.8 % 3.50 [ 1.38, 8.89 ]
Subtotal (95% CI) 21 21 59.8 % 3.50 [ 1.38, 8.89 ]
Total events: 14 (Cannabinoid), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.63 (P = 0.0084)
Total (95% CI) 59 59 100.0 % 0.97 [ 0.04, 20.93 ]
Total events: 14 (Cannabinoid), 7 (Control)
Heterogeneity: Tau2 = 3.89; Chi2 = 4.16, df = 1 (P = 0.04); I2 =76%
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Chi2 = 4.16, df = 1 (P = 0.04), I2 =76%
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Analysis 3.1. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic
monotherapy, Outcome 1 Absence of nausea.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy
Outcome: 1 Absence of nausea
Study or subgroup
Cannabinoid
cotherapy Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Lane 1991 4/17 0/20 10.50 [ 0.61, 182.09 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 4 (Cannabinoid cotherapy), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours [control] Favours [cannabinoid]
Analysis 3.2. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic
monotherapy, Outcome 2 Absence of vomiting.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy
Outcome: 2 Absence of vomiting
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Kleinman 1983 12/28 7/24 100.0 % 1.47 [ 0.69, 3.13 ]
Lane 1991 0/17 0/20 Not estimable
Total (95% CI) 45 44 100.0 % 1.47 [ 0.69, 3.13 ]
Total events: 12 (Cannabinoid), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours control Favours cannabinoid
91Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.3. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic
monotherapy, Outcome 3 Absence of nausea and vomiting.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy
Outcome: 3 Absence of nausea and vomiting
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Lane 1991 8/17 6/20 1.57 [ 0.68, 3.63 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 8 (Cannabinoid), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours control Favours cannabinoid
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Analysis 3.4. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic
monotherapy, Outcome 4 Depression.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy
Outcome: 4 Depression
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Lane 1991 0/20 0/21 Not estimable
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (Cannabinoid), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours cannabinoid Favours control
Analysis 3.5. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic
monotherapy, Outcome 5 Dizziness.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy
Outcome: 5 Dizziness
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Lane 1991 2/20 1/21 2.10 [ 0.21, 21.39 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 2 (Cannabinoid), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 3.6. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic
monotherapy, Outcome 6 Dysphoria.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy
Outcome: 6 Dysphoria
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Lane 1991 3/20 0/21 7.33 [ 0.40, 133.57 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 3 (Cannabinoid), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours cannabinoid Favours control
Analysis 3.7. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic
monotherapy, Outcome 7 Paranoia.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy
Outcome: 7 Paranoia
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Lane 1991 2/20 0/21 5.24 [ 0.27, 102.81 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 2 (Cannabinoid), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours cannabinoid Favours control
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Analysis 3.8. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic
monotherapy, Outcome 8 Sedation.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy
Outcome: 8 Sedation
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Lane 1991 5/20 3/21 1.75 [ 0.48, 6.38 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 5 (Cannabinoid), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours cannabinoid Favours control
Analysis 3.9. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic
monotherapy, Outcome 9 Withdrawal for any reason.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy
Outcome: 9 Withdrawal for any reason
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Lane 1991 5/20 4/21 1.31 [ 0.41, 4.20 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 5 (Cannabinoid), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours cannabinoid Favours control
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Analysis 3.10. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic
monotherapy, Outcome 10 Withdrawal due to adverse event.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy
Outcome: 10 Withdrawal due to adverse event
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Kleinman 1983 2/32 0/32 47.6 % 5.00 [ 0.25, 100.20 ]
Lane 1991 4/20 0/21 52.4 % 9.43 [ 0.54, 164.62 ]
Total (95% CI) 52 53 100.0 % 6.97 [ 0.88, 55.19 ]
Total events: 6 (Cannabinoid), 0 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.84 (P = 0.066)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours cannabinoid Favours control
Analysis 3.11. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic
monotherapy, Outcome 11 Withdrawal due to lack of efficacy.
Review: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Comparison: 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy
Outcome: 11 Withdrawal due to lack of efficacy
Study or subgroup Cannabinoid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Lane 1991 0/20 4/21 0.12 [ 0.01, 2.03 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (Cannabinoid), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours cannabinoid Favours control
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Antineoplastic Agents] explode all trees
#2 MeSH descriptor: [Antineoplastic Combined Chemotherapy Protocols] explode all trees
#3 chemotherap*
#4 #1 or #2 or #3
#5 MeSH descriptor: [Nausea] explode all trees
#6 MeSH descriptor: [Vomiting] explode all trees
#7 nause* or vomit*
#8 emesis* or emetic* or antiemetic* or emetogenic*
#9 #5 or #6 or #7 or #8
#10 MeSH descriptor: [Cannabinoids] explode all trees
#11 MeSH descriptor: [Cannabis] explode all trees
#12 cannab*
#13 dronabinol
#14 nabilone
#15 tetrahydrocannabinol
#16 cesamet
#17 delta-9-THC
#18 delta-9-tetrahydrocannabinol
#19 marinol
#20 #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19
#21 #4 and #9 and #20
Appendix 2. MEDLINE search strategy
1 exp Antineoplastic Agents/
2 exp Antineoplastic Combined Chemotherapy Protocols/
3 chemotherap*.mp.
4 1 or 2 or 3
5 exp Nausea/
6 exp Vomiting/
7 (nause* or vomit*).mp.
8 (emesis* or emetic* or antiemetic* or emetogenic*).mp.
9 5 or 6 or 7 or 8
10 exp Cannabinoids/
11 exp Cannabis/
12 cannab*.mp.
13 marinol.mp.
14 dronabinol.mp.
15 nabilone.mp.
16 tetrahydrocannabinol.mp.
17 cesamet.mp.
18 delta-9-THC.mp.
19 delta-9-tetrahydrocannabinol.mp.
20 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19
21 randomized controlled trial.pt.
22 controlled clinial trial.pt.
23 randomized.ab.
24 placebo.ab.
25 drug therapy.fs.
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26 randomly.ab.
27 trial.ab.
28 groups.ab.
29 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
30 4 and 9 and 20 and 29
Key: mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier
Appendix 3. EMBASE search strategy
1 exp chemotherapy/
2 exp antineoplastic agent/
3 chemotherap*.mp.
4 1 and 2 and 3
5 exp “nausea and vomiting”/
6 (nause* or vomit*).mp.
7 (emesis* or emetic* or antiemetic* or emetogenic*).mp.
8 5 or 6 or 7
9 exp cannabinoid/
10 cannabis/
11 cannab*.mp.
12 marinol.mp.
13 dronabinol.mp.
14 nabilone.mp.
15 tetrahydrocannabinol.mp.
16 cesamet.mp.
17 delta-9-THC.mp.
18 delta-9-tetrahydrocannabinol.mp.
19 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
20 4 and 8 and 19
21 crossover procedure/
22 double-blind procedure/
23 randomized controlled trial/
24 single-blind procedure/
25 random*.mp.
26 factorial*.mp.
27 (crossover* or cross over* or cross-over*).mp.
28 placebo*.mp.
29 (double* adj blind*).mp.
30 (singl* adj blind*).mp.
31 assign*.mp.
32 allocat*.mp.
33 volunteer*.mp.
34 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33
35 20 and 34
Key: [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer,
device trade name, keyword]
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Appendix 4. PsycInfo search strategy
1 antineoplastic drugs/
2 chemotherapy/
3 chemotherap*.mp.
4 1 or 2 or 3
5 nausea/
6 vomiting/
7 nause*.mp.
8 vomit*.mp.
9 (emesis or emetic* or antiemetic* or emetogenic*).mp
10 5 or 6 or 7 or 8 or 9
11 exp cannabinoids/
12 exp cannabis/
13 cannab*.mp.
14 marinol.mp.
15 dronabinol.mp.
16 nabilone.mp.
17 tetrahydrocannabinol.mp.
18 cesamet.mp.
19 delta-9-THC.mp.
20 delta-9-tetrahydrocannabinol.mp.
21 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
22 4 and 10 and 21
key: [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures]
Appendix 5. LILACS search strategy
((MH:D02.455.848.090$ OR MH:B01.650.940.800.575.100.175.500 OR cannab$ OR marinol OR dronabinol OR nabilone OR
tetrahydrocannabinol OR cesamet OR delta-9-THC OR delta-9-tetrahydrocannabinol) AND (MH:nausea or MH:vomiting OR
MH:emetics OR MH:antiemetics OR nausea$ OR vomit$ OR emesis OR emetic$ OR emetogenic$ OR antiemetic$) AND (MH:
D27.505.954.248$ OR MH:E02.183.750.500 OR MH:E02319.077.500 OR MH:E02.319.310.037 OR chemotherap$))
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Based on peer review feedback of a draft of the review and inclusion of clinical experts on the review team, we made a number of post-
protocol amendments.
’Types of Participants’ have changed from “people to ”Adults aged 18 years and over“.
We removed the plan for a subgroup analysis ”by emetic potential of the chemotherapy agent, high versus low emetogenic potential“ and
added a new subgroup analysis ”by history of exposure to chemotherapy, chemotherapy naive versus prior chemotherapy treatment“.T
he primary outcomes we stated in the protocol are listed in the bullet points below. However, we were unable to analyse data for
frequency and severity of nausea or vomiting (or both) due to use of non-valid and reliable measures, and inappropriate analysis of results
reported in the primary studies. We focused on the proportion of people with cancer with complete absence of nausea or vomiting or
both in common with other systematic reviews of treatments for nausea and vomiting.
• Absence of episodes of nausea and vomiting.
• Frequency of nausea and vomiting.
• Severity of nausea.
We also stated that we would only extract data for the outcome ’participant preference’ for the first cross-over period only (erroneously),
and, due to none of the trials reporting this, we extracted responses for the entire study period.
We added three additional adverse effects as secondary outcomes: focal dystonia, extrapyramidal effects and oculogyric crisis.
We did not contact pharmaceutical companies for data on file.
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Methods for future updates
Data extraction and management
For continuous outcomes (severity of nausea measured using a validated symptom scale), we will extract the final value and standard
deviation of the outcome of interest and the number of participants assessed in each treatment arm at the end of follow-up in order to
estimate the mean difference between treatment arms (or standardised mean difference if measured on different scales) and its standard
error.
Data for frequency of nausea or vomiting, or both, may be reported in a number of ways. For data presented as counts (number of
nausea or vomiting (or both) episodes), we will extract the number of events and person-time at risk, if presented, in order to calculate
a nausea and vomiting rate per treatment group. For data presented as continuous data, we will extract the mean number of events
(nausea or vomiting (or both) episodes) in each treatment group. For data presented as categorical data (number of participants who
experience at least five events), we will proceed as described above for dichotomous data.
Data collection and analysis
If the results are statistically significant, we will calculate the number needed to treat for an additional beneficial outcome (NNTB) or
additional harmful outcome (NNTH). For continuous outcomes, we will calculate the difference in means between treatment arms at
the end of follow-up. We will consider the magnitude of the effect of an intervention as at least moderate if the ’effect size’ is superior
to 0.5 (Cohen 1988). For outcomes reported as rates, we will calculate the rate ratio.
Wherever the data are missing or only imputed data are reported, we will contact the trial authors and request the data on the outcomes
only among the participants who were assessed.
Where the trials have multiple treatment groups, we will divide the ’shared’ comparison group into the number of treatment groups
and treat comparisons between each treatment group and the split comparison group as independent comparisons.
Unit of analysis
In future updates it may be possible to:
• obtain data from study authors for each treatment period or summary statistics of the degree of agreement between each person’s
responses, or both;
• adjust the analyses for the dichotomous outcomes to take into account the paired data.
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